

# House of Delegates

---

## Consolidated Documents:

## 2024 ASHP Virtual Regional Delegate Conferences

---

### Contents

1. Regional Delegate Conference Agenda (Virtual Meetings)
  2. Board Reports on Policy Recommendations
  3. Report of the Committee on Resolutions
  4. Important Dates for Amending Policy Recommendations After the RDC
  5. June House of Delegates Meetings at a Glance
  6. June House of Delegates Agenda (Draft)
  7. First Delegate Caucus Agenda
  8. Second Delegate Caucus Agenda
  9. Regional Delegate Conference Antitrust Statement
  10. Memorandum to Delegates: Candidates for ASHP Offices
  11. Report of the ASHP Treasurer
-

# House of Delegates

---

## **AGENDA**

### **2024 ASHP**

### **Virtual Regional Delegate Conferences**

---

Note: The Virtual Regional Delegate Conferences (RDCs) run from 1:00 to 5:30 p.m. ET on April 27 and April 29.

- A. Welcome and Ground Rules**
- B. Virtual RDC Objective**
- C. Review of Virtual RDC Agenda**
- D. Responsibilities of Delegates**
- E. Review of Assigned Policy Recommendations**
- F. How to Follow Up on Virtual RDCs/Keep the Discussion Going**
- G. Review of Important Events**
- H. Open Discussion (time permitting)**
- I. Adjournment**

# House of Delegates

## Board of Directors Report: Policy Recommendations for the May-June 2024 House of Delegates

	<u>Page</u>
COUNCIL ON PHARMACY PRACTICE POLICY RECOMMENDATIONS .....	3
1. Prehospital Management of Medications .....	3
2. Role of Artificial Intelligence in Pharmacy Practices.....	4
3. Independent Prescribing Authority .....	6
4. Pharmacist’s Role on Ethics Committees.....	9
5. Safe Handling and Administration of Hazardous Drugs .....	11
COUNCIL ON PUBLIC POLICY POLICY RECOMMENDATIONS .....	14
1. Order Verification .....	14
2. Liability Protection .....	16
3. State Prescription Drug Monitoring Programs .....	17
COUNCIL ON THERAPEUTICS POLICY RECOMMENDATIONS .....	20
1. Testing for Pregnancy Status .....	20
2. 5-HT <sub>2</sub> Agonist, Entactogen, and Empathogen (Psychedelic) Assisted Therapy.....	21
3. Nonprescription Status of Rescue and Reversal Medications.....	23
COUNCIL ON EDUCATION AND WORKFORCE DEVELOPMENT POLICY RECOMMENDATIONS.....	26
1. Opposition to Pharmacy Jurisprudence Examination Requirement .....	26

- 2. Pharmacy Technician Education Requirements ..... 27
- 3. Implications of Artificial Intelligence for Professional Integrity ..... 29
- 4. Pharmacy Residency Training ..... 29
- COUNCIL ON PHARMACY MANAGEMENT POLICY RECOMMENDATIONS ..... 31
  - 1. Documentation of Patient-Care Services in the Permanent Health Record ..... 31
  - 2. Supporting High Reliability in Pharmacy Practice..... 33
  - 3. Safe Medication Sourcing, Preparation, and Administration in All Sites of Care..... 34
- SECTION OF COMMUNITY PHARMACY PRACTITIONERS POLICY RECOMMENDATION..... 37
  - 1. ASHP Statement on the Community Pharmacist’s Role in the Care Continuum ..... 37

---

# COUNCIL ON PHARMACY PRACTICE

## POLICY RECOMMENDATIONS

---

*The Council on Pharmacy Practice is concerned with ASHP professional policies related to the responsibilities of pharmacy practitioners. Within the Council's purview are (1) practitioner care for individual patients, (2) practitioner activities in public health, (3) pharmacy practice standards and quality, (4) professional ethics, (5) interprofessional and public relations, and (6) related matters.*

Jennifer Tryon, *Board Liaison*

### **Council Members**

Jennifer Morris, *Chair* (Texas)  
Amanda Wollitz, *Vice Chair* (Florida)  
Earnest Alexander (Florida)  
Michelle Chu (California)  
Angela Colella (Wisconsin)  
Kailee Fretland (Minnesota)  
Natalie Goode (Pennsylvania)  
Terri Jorgenson (Maryland)  
Todd Lemke (Minnesota)  
Helen Park (California)  
Josie Quick (North Dakota)  
Aaron Steffenhagen (Wisconsin)  
Emma Waldthausen, *Student* (Alabama)  
Anna Legreid Dopp, *Secretary*

---

### **1. Prehospital Management of Medications**

- 1 To assert that variation in the prehospital management and use of medications is a risk to
- 2 patient safety and continuity of care; further,
- 3 To advocate for pharmacy workforce involvement in clinical and operational decision-
- 4 making for prehospital management and utilization of medications; further,
- 5 To encourage the pharmacy workforce to assume responsibility for medication-related
- 6 aspects of ensuring the continuity of care as patients transition from prehospital care to
- 7 other care settings; further,
- 8 To collaborate with stakeholders involved in prehospital medication-use cycle decisions
- 9 to improve patient safety, minimize variation, and reduce inefficiencies.

**Rationale**

ASHP advocates that the pharmacy workforce “assume responsibility for medication-related aspects of ensuring the continuity of care as patients move from one care setting to another” (ASHP policy 2205). Prehospital management and utilization of medications varies greatly through patient emergency services, transport, and transfers. The pharmacy workforce has established clinical and operational expertise across the spectrum of medication use, which would add value and safety measures to the prehospital management and utilization of medications. That expertise could inform decision-making regarding standardization, management of medication shortages, and prevention of medication errors, among other things. Ensuring pharmacy workforce involvement in these medication-related activities and decisions would optimize medication use, improving prehospital care and patient safety during emergent situations and patient transfers.

**Background**

The Council examined this topic in response to a recommendation from the 2023 House of Delegates. Council members noted that a similar gap in ASHP policy led to the development of ASHP policy 2317, Emergency Medical Kits, and agreed that an ASHP policy position was needed to fill this gap.

**2. Role of Artificial Intelligence in Pharmacy Practice**

- 1 To recognize artificial intelligence (AI) as a tool with tremendous potential to improve  
2 patient care and the medication-use process, which should be implemented with  
3 caution due to potential unforeseen risks; further,
- 4 To encourage healthcare organizations to develop policies, procedures, and guidelines  
5 to determine which care settings, medications, and patient populations are appropriate  
6 candidates for the use of AI; further,
- 7 To advocate for pharmacy workforce involvement and transparency in the decision-  
8 making, design, implementation, and ongoing evaluation of AI-related applications and  
9 technologies that affect medication-use processes and tasks; further,
- 10 To oppose any use of AI that compromises human interaction or replaces ethical  
11 decision-making, professional judgment, or critical thinking or is implemented solely to  
12 reduce healthcare staffing and resources; further,
- 13 To advocate for regulations and standards that permit the use of AI in circumstances in  
14 which it has proven safe and effective.

**Rationale**

Artificial intelligence (AI) is an emerging technology described as intelligent computer programs or software capable of learning human cognition and processes. AI falls under two categories: machine learning (ML) for data set analysis and natural learning processes for information extraction from existing data. In recent years, AI technology has evolved at an immense speed, and healthcare has been increasingly digitizing data, raising two questions: how to best use both to improve patient-specific care on a grand scale without compromising patient safety and outcomes, and how to retain the expertise, autonomy, and humanity (e.g., empathy and compassion) of the interprofessional care team.

The healthcare community recognizes the potential benefit and risk of AI in patient care. Examples of opportunities include but are not limited to optimizing patient health, reducing variation in patient care services, translating evidence to practice, streamlining workflows and creating efficiencies, and reducing cognitive load on the interprofessional care team. Risks may include potential for breaches in patient privacy and safety; failure to incorporate ethical and moral decision-making; lack of transparency; automation biases; and narrow algorithm development that does not account for diverse populations, widening health disparities in undeserved or underrepresented patient populations. Given these risks, pharmacists and other healthcare professionals must retain oversight of AI applications and their implementation. Even if there comes a time when AI technology can account for every possible variable, the healthcare team must retain the right to make the final decisions on patient care to mitigate its inherent risks.

Pharmacy should take a leading role on the interprofessional healthcare team to research, develop, implement, and improve the quality of AI/ML-based clinical models that affect medication-use processes and tasks. The potential for improvement of care, lower costs, and comprehensive medication management could significantly impact healthcare, but healthcare providers must recognize the need for sufficient purview and monitoring to guarantee patient safety and effective therapy. Pharmacists, as leaders in AI health technology, can guide healthcare professionals and future generations on the implementation of AI in healthcare.

**Background**

The Council discussed AI following the Joint Council and Commission Meeting on the Role of Artificial Intelligence in Pharmacy. Their initial focus was on the ethical considerations in AI; however, the Council felt there was a need to discuss how AI impacts pharmacy practice more broadly. The Council agreed on the need for new ASHP policy. The Council also agreed that the ASHP Statement on the Use of Artificial Intelligence in Pharmacy should be revised to address ethical considerations for AI in healthcare and pharmacy practice, such as what tasks should always be performed by a human and never be replaced by AI, and what ethical considerations are needed for initial evaluation, implementation, and ongoing quality assurance of AI technologies.

### 3. Independent Prescribing Authority

- 1 To affirm that prescribing is a collaborative process that includes patient assessment,  
2 understanding of the patient’s diagnoses, evaluation and selection of available  
3 treatment options, monitoring to achieve therapeutic outcomes, patient education, and  
4 adherence to safe and cost-effective prescribing practices; further,
- 5 To recognize that pharmacists are highly trained medication experts on the  
6 interprofessional care team capable of making independent and autonomous evidence-  
7 based decisions on medication therapy management; further,
- 8 To advocate that pharmacists have independent and autonomous authority to initiate,  
9 modify, and deprescribe all schedules and classes of medications; further,
- 10 To advocate that healthcare delivery organizations establish credentialing and  
11 privileging processes for pharmacists that delineate scope of practice, support  
12 pharmacist prescribing, and ensure that pharmacists who prescribe are accountable,  
13 competent, and qualified to do so; further,
- 14 To advocate that all pharmacists have a National Provider Identifier that is recognized  
15 by payers.

*Note: This policy would supersede ASHP policies 2236 and 2251.*

#### **Rationale**

Pharmacists are highly trained medication experts skilled in providing comprehensive medication management (CMM) services across the continuum of care. Nearly all states include pharmacist prescribing authority within their state practice acts, although those acts differ in how pharmacist prescribing authority is described, terminology used, and the degree of prescribing autonomy (i.e., autonomous or collaborative). Regulations at the state level are critical to ensuring that pharmacists can seamlessly provide CMM services within the interprofessional team and to the top of their skills and abilities. Pharmacists are a core healthcare team member, well-positioned to provide high-quality, cost-effective care that increases patient access and reduces the burden on other healthcare providers. Hundreds of studies published in peer-reviewed literature, conducted throughout a variety of organizations and health systems, have consistently demonstrated the benefits of pharmacist-directed patient care across a variety of clinical practice settings. A 2010 comprehensive systematic review of 298 studies of U.S. pharmacists’ effect as a member of the patient care team found positive results on therapeutic and safety metrics (Chisholm-Burns MA, Kim Lee J, Spivey CA, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. *Med Care*. 2010; 48:923-33).

Autonomous prescribing allows pharmacists to be fully optimized as a part of the

interprofessional healthcare team and ensures that their skills are used to the fullest potential to allow them to be responsible and accountable and fully execute CMM treatment plans. Pharmacist prescribing is implicit to interprofessional care delivery, but the form and manner of pharmacist prescribing varies among health systems and organizations. Independent and autonomous drug therapy decision-making by pharmacists is already common and accepted by other licensed practitioners (e.g., physicians, physician assistants, and nurse practitioners). Practitioners participating in interprofessional teams that include pharmacists rely on the knowledge, demonstrated competency, and expertise of those pharmacists for CMM. Pharmacists in specialty practice areas such as anticoagulation management, solid organ transplant, and nutrition support have long functioned in roles in which autonomous prescribing authority has improved clinical outcomes in the management and monitoring of medication therapy. In settings such as the Indian Health Service and Veterans Health Administration systems, prescribing authority for pharmacists providing CMM services has been in place for over 40 years and has demonstrated positive clinical impact and increased patient access across the continuum of care.

Many health systems authorize pharmacists to manage drug therapy by enacting pharmacy and therapeutics committee policies that require use of medical staff protocols and physician oversight for pharmacist-initiated orders. While this model works effectively for specific scenarios (e.g., management of population-specific patients), it does not allow the pharmacist to fully function and fulfill the CMM needs of their patients. Depending on the patient, medication, and degree of trust with the pharmacist, physicians often delegate therapeutic decision-making and medication treatment planning to pharmacists, based on the trust relationship developed through the interprofessional team and shared experiences in successfully dealing with challenging clinical situations, rather than through formal collaborative practice agreements. Common examples of pharmacist prescribing include independently managing symptoms and adverse events in oncology patients, identifying and resolving drug-induced disease or problems, managing anticoagulant therapy for patients whose clinical status falls outside specified parameters, and responding to general directives to simply “fix the problem” when medication therapy is indicated. Further, there are settings of care and pharmacy practice models that allow for autonomous and accountable prescribing authority by pharmacist practitioners as core component of CMM, without the need for collaborative practice authority for specific patients or populations. Pharmacist autonomous prescribing authority should be the gold standard for practice, especially when appropriate credentialing and privileging is in place and there is a separation of duties to ensure that a prescribing pharmacist is not responsible for the processing and dispensing of that medication order.

Pharmacists who prescribe must be recognized by payers and receive equitable payment for performing these advanced practice services. All pharmacist prescribers on the interprofessional team must possess a National Provider Identifier to monitor the care provided as well as reimburse for services rendered. Credentialing and privileging of individual healthcare providers is essential for determining who is authorized to prescribe and should ensure the appropriate evaluation of the quality of care provided. The credentialing procedures used to establish pharmacists’ competency to prescribe must ensure that patients receive treatment from highly qualified caregivers. In addition to verifying appropriate education,

licensure, and certification, the process should include

- the same transparency and rigor applied to other prescribers,
- criteria used to measure patient care quality, and
- peer review by similar or higher-level peers (i.e., pharmacist prescribers or other licensed practitioners who are authorized to prescribe).

Healthcare organizations should use privileging methods that establish the scope of practice and clinical services that pharmacists are authorized to provide commensurate with their demonstrated competency within an area or areas of clinical expertise. The practice of credentialing and privileging should be consistent between hospitals health systems, accountable care organizations, and other organizations where the pharmacists function as a part of the interprofessional team. Finally, interdisciplinary health professional training programs should incorporate the concept of pharmacist prescribing in a standard way to ensure consistency amongst pharmacists practicing in similar practice settings and with similar levels of responsibilities.

### **Background**

The Council examined this topic in response to a recommendation from the 2023 House of Delegates to consolidate and harmonize ASHP policies related to pharmacist prescribing authority. The Council consolidated ASHP policies 2251, Qualifications and Competencies Required to Prescribe Medications, and 2236, Pharmacist Prescribing in Interprofessional Patient Care, and updated them for readability and consistency as follows (underscore indicates new text; ~~striketrough~~ indicates deletions):

To affirm that prescribing is a collaborative process that includes patient assessment, understanding of the patient’s diagnoses, evaluation and selection of available treatment options, monitoring to achieve therapeutic outcomes, patient education, and adherence to safe and cost-effective prescribing practices; further, **[from policy 2251]**

~~To affirm that safe prescribing of medications, performed independently or collaboratively, requires competent professionals who complement each others’ strengths at each step. [from policy 2251]~~

To recognize that pharmacists are highly trained medication experts on the interprofessional care team capable of making independent and autonomous evidence-based decisions on medication therapy management; further,

To advocate that pharmacists have independent and autonomous authority to initiate, modify, and deprescribe all schedules and classes of medications; further,

To advocate that healthcare delivery organizations establish credentialing and privileging processes for pharmacists that delineate scope of practice, support pharmacist prescribing, and ensure that pharmacists who prescribe are accountable, competent, and qualified to do so; further, **[from policy 2236]**

~~To advocate for comprehensive medication management that includes autonomous prescribing authority for pharmacists as part of optimal interprofessional care; further, [from policy 2236]~~

~~To advocate that all pharmacists on the interprofessional team have a National Provider Identifier (NPI); further, that is recognized by payers. [from policy 2236]~~

~~To advocate that payers recognize pharmacist NPIs. [from policy 2236]~~

The Council drafted the new second clause (“To recognize that pharmacists are highly trained medication experts...”) to emphasize that pharmacists have the skills to make decisions regarding medication therapy management, including prescribing. The Council drafted the new third clause (“To advocate that pharmacists have independent and autonomous authority...”) to capture the intent of the clause struck from policy 2236 and to more clearly define the scope of pharmacists’ prescribing authority.

#### 4. Pharmacist’s Role on Ethics Committees

- 1 To advocate that pharmacists should be included as members of, or identified as a
- 2 resource to, hospital and health-system ethics committees; further,
- 3 To encourage pharmacists to actively seek ethics consultations or solicit input from their
- 4 institution’s ethics committee, as appropriate; further,
- 5 To encourage pharmacists serving on ethics committees to seek advanced training in
- 6 healthcare ethics.

*Note: This policy would supersede ASHP policy 1403.*

#### **Rationale**

Many hospitals have a committee or other process by which they consider ethical decisions related to patient care. Many issues that face these committees involve medications, yet often pharmacists do not serve on the committee or are not directly involved in the decision-making process. The number of ethical issues involving medications is expected to increase, given many new and unique drug products coming into the market. These include patient access to high-cost medications, considerations during medication shortages, and other ethical considerations that surface as part of the formulary process. Pharmacist involvement would better inform these committees and consultations. To effectively contribute to decision-making on ethics, pharmacists will require advanced education on the subject.

#### **Background**

The Council reviewed ASHP policy 1403, Pharmacist’s Role on Ethics Committees, as part of

sunset review and voted to recommend amending it as follows (underscore indicates new text; ~~strikethrough~~ indicates deletions):

To advocate that pharmacists should be included as members of, or identified as a resource to, hospital and health-system ethics committees; further,

To encourage pharmacists to actively seek ethics consultations or solicit input from their institution's ethics committee, as appropriate; further,

To encourage pharmacists serving on ethics committees to seek advanced training in healthcare ethics.

This policy was last reviewed in 2019 by the Council on Pharmacy Practice. The Council determined the policy needed to be revised to capture pharmacists serving as an expert or resource to ethics committees. Council members also indicated that ASHP needs to offer more education and resources in ethics and ethical decision-making. In particular, the Council felt more programming is needed related to ethical decisions specific to medication use, medication shortages, and high-cost medications.

## 5. Safe Handling and Administration of Hazardous Drugs

- 1 To advocate that pharmaceutical manufacturers eliminate surface contamination on  
2 packages and vials of hazardous drugs (HDs); further,
- 3 To inform pharmacists and other personnel of the potential presence of surface  
4 contamination on the packages and vials of HDs; further,
- 5 To advocate that all healthcare settings proactively conduct an interprofessional  
6 assessment of risk for exposure to HDs during handling and administration, including the  
7 use of closed-system transfer devices (CSTDs); further,
- 8 To advocate for pharmacist involvement in the development of policies, procedures, and  
9 operational assessments regarding administration of HDs, including when CSTDs cannot  
10 be used; further,
- 11 To advocate that the Food and Drug Administration require standardized labeling and  
12 package design for HDs that would alert handlers to the potential presence of surface  
13 contamination, including development of CSTD-compatible, ready-to-administer HD  
14 products; further,
- 15 To encourage healthcare organizations, wholesalers, and other trading partners in the  
16 drug supply chain to adhere to published standards and regulations.

*Note: This policy would supersede ASHP policies 1615 and 1902.*

### **Rationale**

Hazardous drugs (HDs) present well-known risks to healthcare workers who handle them. Most HDs are administered orally or intravenously; however, other routes of administration are sometimes used, such as intrathecal, intraventricular, or intravesicular administration, or perfusion into a vessel or organ cavity. These procedures are becoming more common. Healthcare providers are required to use personal protective equipment and other protective devices, such as closed-system transfer devices (CSTDs), when the dosage form allows. The protective precautions required for administration through these routes is well described in United States Pharmacopeia (USP) General Chapter 800, the ASHP Guidelines on Handling Hazardous Drugs, the Oncology Nursing Society's Safe Handling of Hazardous Drugs, and other sources.

HDs are sometimes administered through other routes (e.g., Ommaya reservoirs, intraperitoneal infusion) for which protective precautions are not as well described or CSTD use is not possible. ASHP encourages all healthcare settings to conduct an interprofessional, proactive assessment of the risk of such procedures to assess the potential exposure risks for healthcare providers and identify mitigating measures. Given their depth of knowledge

regarding the handling of HDs, pharmacists should be involved in the development of policies, procedures, and operational assessments regarding administration of HDs in such circumstances. To reduce the risks to healthcare providers, ASHP encourages device and pharmaceutical manufacturers and the Food and Drug Administration (FDA) to deploy new production and processing standards to mitigate exposures, including labeling and package design that alerts handlers to the possibility of contamination. In addition, manufacturers and the FDA should develop CSTD-compatible, ready-to-administer HD drug products with the goal that CSTDs be utilized for all routes of administration of HD products as a best practice. However, when such use is not possible, an assessment of risk could identify gaps and ensure there are pharmacy-guided policies to address the handling, compounding, and administration for all healthcare staff coming into contact with HDs during administration via nontraditional routes. Such policies could also address any specialized training for staff in procedural areas, or the availability of a HD-specialized trained staff member to assist in the administration of the drug (e.g., a “chemo nurse”).

The outer surfaces of vials of hazardous drugs have been shown to be contaminated with hazardous substances, and pharmacy and other personnel handling those vials may unknowingly be exposed. ASHP advocates that individuals involved in drug distribution, receiving, and inventory control adhere to safe handling guidelines, including ASHP guidelines and United States Pharmacopeia Chapter 800, to avoid undue exposure to hazardous substances but recognizes the limits of these best practices. Pharmaceutical manufacturers have a responsibility to provide vials that are devoid of surface contamination by ensuring adequate vial-cleaning procedures such as using decontamination equipment and protective sleeves during the manufacturing process.

### **Background**

The Council reviewed ASHP policy 1902, Safe Administration of Hazardous Drugs, as part of sunset review, and voted to recommend consolidating it with ASHP policy 1615, Protecting Workers from Exposure to Hazardous Drugs, as follows (underscore indicates new text; ~~strikethrough~~ indicates deletions):

To advocate that pharmaceutical manufacturers eliminate surface contamination on packages and vials of hazardous drugs (HDs); further, **[from policy 1615]**

To inform pharmacists and other personnel of the potential presence of surface contamination on the packages and vials of HDs ~~hazardous drugs~~; further, **[from policy 1615]**

To advocate that all healthcare settings proactively conduct an interprofessional assessment of risk for exposure to ~~hazardous drugs~~ (HDs) during handling and administration, including the use of ~~when~~ closed-system transfer devices (CSTDs) ~~cannot be used~~; further, **[from policy 1902]**

To advocate for pharmacist involvement in the development of policies, procedures, and operational assessments regarding administration of HDs, including when CSTDs

cannot be used; further, **[from policy 1902]**

To advocate that the Food and Drug Administration require standardized labeling and package design for HDs ~~hazardous drugs~~ that would alert handlers to the potential presence of surface contamination; ~~further,~~ **[from policy 1615]**

~~To encourage device and pharmaceutical manufacturers and the Food and Drug Administration to foster~~ including development of CSTD-compatible, ready-to-administer HD products; ~~further,~~ **[from policy 1902]**

To encourage healthcare organizations, wholesalers, and other trading partners in the drug supply chain to adhere to published standards and regulations, ~~such as ASHP guidelines and United States Pharmacopeia Chapter 800, to protect workers from undue exposure to hazardous drugs.~~ **[from policy 1902]**

---

# COUNCIL ON PUBLIC POLICY

## POLICY RECOMMENDATION

---

*The Council on Public Policy is concerned with ASHP professional policies related to laws and regulations that have a bearing on pharmacy practice. Within the Council's purview are (1) federal laws and regulations, (2) state laws and regulations, (3) analysis of public policy proposals that are designed to address important health issues, (4) professional liability as defined by the courts, and (5) related matters.*

Sam Calabrese, *Board Liaison*

### **Council Members, 2022-2023**

Adam Porath, *Chair* (Nevada)  
Caryn Belisle, *Vice Chair* (Massachusetts)  
Jordan Dow (Wisconsin)  
Courtney Henry (Virginia)  
William Kernan (Florida)  
Vivian Mao, *Student* (California)  
Kimberly Mehta (Pennsylvania)  
Rachel Root (Minnesota)  
Keenan Ryan (New Mexico)  
Harshal Shukla (New York)  
Cassie Schmitt (Minnesota)  
Kenric Ware (South Carolina)  
Jillanne Schulte Wall, *Secretary*

---

### **1. Order Verification**

- 1 To advocate that a prescriber should not be solely responsible for medication ordering,
- 2 dispensing, and administration as well as any patient monitoring and evaluation, except
- 3 when a double check would limit patient access to care.

### **Rationale**

As pharmacy practice has evolved to include more direct patient care services, oversight of these services has not kept pace. This trend was exacerbated by the COVID-19 pandemic, which ushered in new test-to-treat models for pharmacy teams and introduced new flexibilities into telehealth. As care has shifted, pharmacists may be placed in situations in which they are overseeing many aspects of medication use, from independent prescribing to dispensing, without any additional verification checks. Other clinicians, including physicians and nurse practitioners, may also be in similar positions. Regardless of setting, without adequate patient safety safeguards (e.g., high-reliability process, technology and/or human review), placing one clinician in charge of the elements of medication-use process related to ordering, dispensing and administration, as well as any patient evaluation and monitoring, increases the risk for errors and adverse outcomes. While human checks are preferable for high-risk drugs, nothing in this policy should be considered to oppose appropriate autoverification of orders.

**Background**

The Council discussed how independent prescribing authority has shifted pharmacy practice, resulting in situations in which a single pharmacist is responsible for all patient-focused elements of the medication-use process (e.g., ordering, administration, dispensing, and evaluation and/or monitoring). The Council noted that this is also the case for physicians and certain nonphysician practitioners, but agreed that regardless of clinician type, checks are needed to ensure patient safety. The Council reviewed both ASHP policies 2133, Optimal Pharmacy Staffing Levels, and 2246, Autoverification of Medication Orders, and concluded that this issue merited its own policy rather than inclusion in an existing policy.

The Council discussed the Board's recommended edits to the policy, but felt that they did not fully capture the Council's intent. Specifically, the Council reiterated its concerns that no clinician, including pharmacists, should be placed in a position in which they maintain responsibility for the entire medication-use process without any checks. The Council agreed that checks could be provided by technology and should not be the basis for limiting patient access to treatment when such checks were unavailable (particularly in rural and/or underserved areas). The Council reworked the original policy language to incorporate the last portion of the Board's revisions and suggested some edits to the rationale, as indicated above. The Council felt strongly that this policy would not impede uptake of test-to-treat models, given that the language is inclusive of all providers and makes allowances for situations in which additional checks are not feasible.

---

# COUNCIL ON PUBLIC POLICY

## POLICY RECOMMENDATIONS

---

*The Council on Public Policy is concerned with ASHP professional policies related to laws and regulations that have a bearing on pharmacy practice. Within the Council's purview are (1) federal laws and regulations, (2) state laws and regulations, (3) analysis of public policy proposals that are designed to address important health issues, (4) professional liability as defined by the courts, and (5) related matters.*

Vivian Bradley Johnson, *Board Liaison*

### **Council Members, 2023-2024**

Caryn Belisle, *Chair* (Massachusetts)  
Kimberly Mehta, *Vice Chair* (Pennsylvania)  
Cheri Briggs (Delaware)  
Jordan Dow (Wisconsin)  
Jonathan "Scott" Hayes (Kentucky)  
Courtney Henry (Virginia)  
Rohin Kasudia (District of Columbia)  
Amanda Leiman (Wisconsin)  
Michelle Reyes, *Student* (Colorado)  
Rachel Root (Minnesota)  
Cassandra Schmitt (Minnesota)  
Harshal Shukla (New York)  
Tyler Vest (North Carolina)  
Jillanne Schulte Wall, *Secretary*

---

## **2. Liability Protection**

- 1 To advocate that pharmacists be able to provide evidence-based dispensing and care to
- 2 patients without fear of criminal or civil legal consequences, harassment, or liability;
- 3 further,
- 4 To advocate that protection against liability extend to referrals for out-of-state care and
- 5 for dispensing to patients from another state.

### **Rationale**

In some states, pharmacists face potential civil or criminal liability for providing certain evidence-based patient care, including services related to reproductive health, gender-affirming care, and prevention and post-prophylaxis for HIV. Subjecting pharmacists to such liability for providing evidence-based patient care not only inappropriately infringes on the practice of pharmacy, it increases risks to patients. Given the chilling effect of the laws impeding evidence-based patient care services, patient access to services may be reduced or eliminated. Treatment delays, particularly for time-sensitive care related to reproductive health and provision of post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP), adversely impact patient care and outcomes and may result in patient or fetal mortality. Further, fear of prosecution could unduly limit not only the number of pharmacists willing or able to provide

these services, but also significantly hinder training and specialization in these areas in the next generation of clinicians, damaging our nation's clinical pipeline.

### **Background**

The Council reviewed ASHP policy 2250, Access to Reproductive Health Services, to ensure that no changes were needed to address state law shifts following the Dobbs decision. The Council felt that no changes to policy 2250 were needed, but voiced concern about the growing threat of prosecution or civil liability for pharmacists providing evidence-based reproductive health, gender-affirming care, and PEP and PrEP. The Council felt that ASHP should provide education and analysis of new state laws to avoid chilling effects related to fear of prosecution or liability. Further, the Council recommended some edits to the rationale of policy 2250 to note the need for education related to potential areas of liability (e.g., reproductive health, PEP and PrEP, and gender-affirming care).

### **3. State Prescription Drug Monitoring Programs**

- 1 To support continued state implementation of prescription drug monitoring programs
- 2 that collect real-time, relevant, and standard information from all dispensing outpatient
- 3 entities about controlled substances and monitored prescriptions; further,
  
- 4 To advocate that such programs seek adoption into health information exchanges to
- 5 best integrate into electronic health records and to allow prescribers, pharmacists, and
- 6 other practitioners to proactively monitor data for appropriate assessment and
- 7 dispensing; further,
  
- 8 To advocate that such programs improve their interstate data integration to enhance
- 9 clinical decision-making and end-user satisfaction; further,
  
- 10 To encourage policies that allow practicing pharmacists to gain access to databases
- 11 without holding licensure in each state; further,
  
- 12 To promote research on the effects of prescription drug monitoring programs and
- 13 electronic health record programs on opioid prescribing, dispensing, misuse, morbidity,
- 14 and mortality.

*Note: This policy would supersede ASHP policy 1408.*

### **Rationale**

ASHP recognizes the important contributions to public health made by state prescription drug monitoring programs (PDMPs). To be effective, these programs need to be mandatory; must

collect standardized, relevant, and real-time information for analysis and comparison among states; and need to be universal.

All states have implemented PDMPs, with the final state, Missouri, implementing its on January 20, 2023. While this is a great step forward, continued improvement of PDMP utilization is required. A recent review of PDMP reviews by Tay et al. in the Journal of Drug and Alcohol Dependence identified the following barriers still exist: PDMP system-related (i.e., usability, data quality), end-user related (i.e., satisfaction, workflow efficiency), and broader issues (i.e., electronic health record (EHR) integration, data sharing). More importantly, not all states mandate provider use of PDMP prior to controlled substance prescribing, and states that do mandate its use are slow to hold providers/pharmacists accountable for not using it. Due to these factors, it is difficult for practitioners to make relevant clinical decisions.

For states to see improvement in PDMPs there needs to be improved data sharing between different jurisdictions, enhanced interoperability with EHRs and information exchanges, and increased evidence of PDMPs' impacts on patient outcomes to increase utilization. Finally, adequate state and federal funding is essential to sustain the viability of these programs and to encourage research, education, and implementation of best practices in PDMPs.

### **Background**

The Council reviewed ASHP policy 1408, State Prescription Drug Monitoring Programs as part of sunset review and voted to recommend amending it as follows (underline indicates new text; ~~strikethrough~~ indicates deletions):

To ~~advocate for mandatory, uniform~~ support continued state implementation of prescription drug monitoring programs that collect real-time, relevant, and standard information from all dispensing outpatient entities about controlled substances and monitored prescriptions; further,

~~To advocate that the design of these programs should balance the need for appropriate therapeutic management with safeguards against fraud, misuse, abuse, and diversion; further,~~

To advocate that such programs seek adoption into health information exchanges to best integrate into ~~be structured as part of~~ electronic health records and ~~exchanges~~ to allow prescribers, pharmacists, and other practitioners to proactively monitor data for appropriate assessment and dispensing; further,

~~To advocate for full interstate integration to allow for access by prescribers, pharmacists, and other qualified designees across state lines; further,~~

~~To advocate for federal and state funding to establish and administer these programs; further,~~

~~To promote research, education, and implementation of best practices in prescription drug monitoring programs.~~

To advocate that such programs improve their interstate data integration to enhance clinical decision-making and end-user satisfaction; further,

To encourage policies that allow practicing pharmacists to gain access to databases without holding licensure in each state; further,

To promote research on the effects of prescription drug monitoring programs and electronic health record programs on opioid prescribing, dispensing, misuse, morbidity, and mortality.

The Council updated the wording of the policy to reflect the fact that all states have now adopted PDMPs. It also updated language around integration of PDMP usage into EHRs and information exchanges to better reflect current technology and usage.

---

# COUNCIL ON THERAPEUTICS

## POLICY RECOMMENDATIONS

---

*The Council on Therapeutics is concerned with ASHP professional policies related to medication therapy. Within the Council's purview are (1) the benefits and risks of drug products, (2) evidence-based use of medicines, (3) the application of drug information in practice, and (4) related matters.*

Vickie L. Powell, *Board Liaison*

### **Council Members**

Russel Roberts, *Chair* (Massachusetts)  
Kate Ward, *Vice Chair* (Nevada)  
Scott Bolesta (Pennsylvania)  
Rachel Bubik (Minnesota)  
Simran Chahal, *Student* (Tennessee)  
Jerika Lam (California)  
Zahra Nasrazadani (Kansas)  
Kunal Patel (Georgia)  
Martha Roberts (Rhode Island)  
David Silva (Connecticut)  
Thomas Szymanski (West Virginia)  
Brittany Tschean (Delaware)  
Vicki Basalyga, *Secretary*

---

### **1. Testing for Pregnancy Status**

- 1 To affirm that pregnancy testing should occur only with informed consent and only when
- 2 the test results would change medical management; further,
  
- 3 To affirm that a positive pregnancy test should not compromise the integrity of evidence-
- 4 based, patient-centered care.

### **Rationale**

Screening and testing for the pregnancy status of patients prior to admission to a hospital or surgical center or before initiation of a teratogenic drug therapy has long been a routine practice, as the pregnancy status of a patient has many ethical and legal considerations when medical management is considered for patient care. Chief pharmacy officers often oversee laboratory medicine departments, and pharmacists are often involved in creating protocols and order sets in which pregnancy testing and screenings are embedded and as a result are key stakeholders.

It is important to note that this policy pertains to testing without informed consent when therapy may need to be changed due to a positive test. The balance between unnecessary testing and testing when initiating a medication therapy is supported by a [2015 study](#) that found that pregnancy assessment was underutilized in the emergency department when patients were prescribed a pregnancy category D or X drug. This policy does not advocate

that healthcare professionals should not include pregnancy screening as a part of a patient history, only that pregnancy testing should occur only with informed consent and not be a requirement for care. The incidence of unknown pregnancy in adult women presenting to a hospital for surgical procedures varies from 0.125 to 1.2%, depending on the procedure.

This policy also aligns ASHP with the American Society of Anesthesiologists [statement](#) that recommends “pregnancy testing may be offered to female sex patients of childbearing age and for whom the result would alter the patient’s management, but testing should not be mandatory. Informed consent or assent of the risks, benefits, and alternatives related to preoperative pregnancy testing should ideally be obtained. Best practice may employ shared decision-making between patients and providers.”

### **Background**

The Council reviewed and discussed ASHP policy positions 2315, Responsible Medication-Related Clinical Testing and Monitoring; 0013, Patient’s Right to Choose; and 2320, Pharmacoequity, in their discussion about this topic, and concluded that a standalone policy is needed.

## **2. 5-HT<sub>2</sub> Agonist, Entactogen, and Empathogen (Psychedelic) Assisted Therapy**

- 1 To recognize that psychedelic-assisted therapy (PAT) has demonstrated therapeutic  
2 potential and should be further researched; further,
- 3 To recognize that in PAT there is not a standardized product subject to the same  
4 regulations as a prescription drug product, and to support the development of  
5 standardized formulations of psychedelics that would provide consistent potency and  
6 quality; further,
- 7 To encourage state boards of pharmacy, regulatory agencies, and safety bodies with an  
8 interest in PAT to promote research best practices and regulatory standards for  
9 medication preparation, compounding, and administration to ensure safety and quality;  
10 further,
- 11 To advocate that when psychedelics are used for PAT, healthcare providers, including  
12 pharmacists, should assess patients for medical, pharmacologic, and psychosocial  
13 contraindications prior to use and provide medical assistance as needed.

### **Rationale**

There has been growing interest in the therapeutic potential of psychedelic drugs for use in the treatment of conditions such as depression, posttraumatic stress disorder, substance use disorders, and other conditions. The U.S. Food and Drug Administration (FDA) includes among these psychedelic drugs the “classic psychedelics,” typically understood to be 5-HT<sub>2</sub> agonists

such as psilocybin and lysergic acid diethylamide (LSD), as well as entactogens or empathogens such as 3,4-methylenedioxymethamphetamine (MDMA). As a result of the growing interest, the FDA [issued guidance](#) that provides general considerations to sponsors developing psychedelic drugs for treatment of medical conditions.

Many studies report that psychedelic compounds are associated with few adverse events in trials, but the populations studied are not generalizable to the larger population. Psychological safety is a potential concern, and psychological distress is common, though not necessarily harmful in the long term. Increased blood pressure and heart rate due to the distress experienced during the administration session may put individuals with uncontrolled blood pressure or coronary artery disease at risk of ischemic events and may be considered a relative contraindication. Psychiatric illnesses, including schizophrenia, psychosis, and bipolar disorder, are considered a likely contraindication to psychedelic therapy. Drug-drug interactions of psilocybin, including tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, and QT interval-prolonging medications, are of concern and underscore the importance of pharmacists in the management of policies and practices related to the use of psychedelic compounds. Small sample sizes, a lack of diversity in enrollment, a lack of effective blinding, varied doses studied, and selective enrollment are just some of the critiques of trials assessing the use of psychedelic compounds. Psilocybin has been studied mainly in the treatment of psychological distress associated with life-threatening illnesses and major depressive disorder, while MDMA has been studied most extensively in the treatment of posttraumatic stress disorder. Despite promising results of some of the studies, the limitations of the studies prevent firm conclusions from being drawn.

In 2023, the American Medical Association also [released](#) new Current Procedural Terminology (CPT) III codes for Continuous In-Person Monitoring and Intervention During Psychedelic Medication Therapy. The code will provide a mechanism to track and report on the delivery of psychedelic treatments and will cover multiple psychedelic compounds with psychological support models, if approved, as well as various staffing structures, and numbers and credentials of qualified healthcare professionals.

Currently, psychedelic compounds with proposed therapeutic benefit, including psilocybin and MDMA, remain Schedule I substances, with no recognized therapeutic uses. Two states, Oregon and Colorado, have passed laws allowing the legal consumption of psychedelic compounds. Medical organizations have expressed concern about state efforts to circumvent federal laws through this approach, particularly when in the guise of medical treatment. In Oregon, for example, the administration of psychedelics is accompanied by assisted psychotherapy to maximize the possible therapeutic benefits. Prior to administration of the psychedelic compound, the individual will meet with a facilitator in a “preparation” session to review safety and support planning, transportation, and expectations for the administration of the psychedelic compound. The individual is then administered the dose under the supervision of the facilitator. Although these individuals are encouraged to share their past medical histories with the facilitator, it is not required, and the screening needed to ensure an appropriately selected client may fail to detect contraindications or significant drug-drug interactions. Furthermore, facilitators are required to have only a high school diploma and are not required to undergo medical training. This lack of training is of particular concern because individuals who are not trained medical professionals are likely unable to distinguish between

medical emergencies and the side effects of the psychedelic compounds.

ASHP policy also aligns with the [American Psychiatric Association position](#) that recognizes the emerging scientific evidence for using psychedelic drugs within the context of approved investigational studies and that “clinical treatments should be determined by scientific evidence in accordance with applicable regulatory standards and not by ballot initiatives or popular opinion.”

It is important to recognize that mushrooms containing psilocybin have long been used for rituals and religious ceremonies around the world. As this use falls within indigenous cultural and religious traditions and is not intended as a medical treatment, this policy does not address those uses.

### **Background**

The Council reviewed the current evidence supporting the use of psychedelics along with the federal and state laws surrounding their use. Council members also discussed the trend of state law circumventing federal law for Schedule I substances and acknowledged that, despite promising results, the state approach to permitting use is concerning. The Council also recognized that although the ideal approach to PAT would be through controlled studies, PAT outside of investigational studies is already expanding, so the policy is written to reflect this reality and to encourage the presence of a medical professional at sites where PAT is provided. The Council also suggested that since more states are enacting legislation permitting the use of psychedelics, ASHP could provide resources on drug-drug interactions, toxicology, and education on PAT.

### **3. Nonprescription Status of Rescue and Reversal Medications**

- 1 To support the over-the-counter (OTC) status of medications intended for evidence-
- 2 based rescue use or reversal of potentially fatal events; further,
  
- 3 To work with federal, state, and local governments and others to improve the rescue and
- 4 reversal medication development and supply system to ensure an adequate and
- 5 equitably distributed supply of these medications; further,
  
- 6 To advocate that all insurers and manufacturers maintain coverage and limits on out-of-
- 7 pocket expenditure so that patient access to rescue and reversal medications is not
- 8 compromised; further,
  
- 9 To support and foster standardized education and training on the role of rescue and
- 10 reversal medications and their proper administration, safe use, and appropriate follow-
- 11 up care.

### **Rationale**

As part of public health initiatives, certain medications used for rescue and reversal have

moved from prescription to over-the-counter (OTC) status. The opioid reversal agent naloxone is the most recent approval, with [naloxone nasal spray approved](#) in March of 2023 to help combat the opioid epidemic in the United States. Rescue and reversal medications such as naloxone and epinephrine require an additional level of action from patients and caregivers because they are used to initially treat life-threatening conditions, in contrast to other OTC agents. These patients will often require an additional level of care to monitor for safety and potential adverse events in the event of an opioid overdose or anaphylactic reaction. Therefore, it is important that rescue and reversal medications considered for OTC status have evidence that supports their use.

As barriers to access are removed, patient demand for these life-saving agents will almost certainly skyrocket, aligning with the intended purpose of such initiatives. To forestall the possibility of counterproductive market shortages, efforts to support and enhance manufacturing processes should be bolstered, with the U.S. Food and Drug Administration (FDA) likely being the most effective entity for these interventions. These interventions may include new drug application (NDA) provisions that require a certain threshold of product availability prior to OTC approval or a mandate that all manufacturers of an approved product transition their agent-specific supply chain to OTC distribution. Further, the FDA should optimize the NDA process itself, which may include a fast track for rescue and reversal medications, subsidies for all or part of the process, or standardized product labeling — which may serve the dual purpose of also supporting patient education initiatives — and other such measures.

Similarly, pricing for rescue and reversal medications should be minimized as much as possible, including efforts to eliminate patient cost entirely. OTC status often results in loss of third-party payer coverage, although there are notable exceptions to this trend (e.g., aspirin, vitamin D). The Affordable Care Act established a precedent for requiring insurer coverage of preventive drugs, and similar provisions could be made for rescue and reversal agents. Government efforts could include other related efforts, such as developing manufacturing cost subsidies, supporting tax-exempt status designations, and augmenting the wholesale distribution process and related infrastructure.

Finally, because the use of rescue and reversal medications often occurs in an emergency situation, easy-to-understand instructions on how to use these drugs and how to escalate if a person does not respond should be encouraged by all manufacturers. These instructions should be designed, tested, and validated in a similar design to the Drug Fact Label created by the FDA, which is designed to assess whether all the components of the product with which a user would interact could be used safely and effectively as intended.

### **Background**

The Council discussed the approval of naloxone spray as an OTC agent and the potential for other rescue and reversal medications to become OTC. In light of the FDA announcement of naloxone's change to OTC status, the Council reviewed ASHP policy position 2211, Naloxone Availability, for potential updates and found that, even with the recent change to OTC status, the policy language is still relevant and did not require updating. When discussing other drugs, injectable epinephrine was the next drug that was considered. OTC inhaled epinephrine is OTC as the branded Primatene Mist HFA, which is indicated for treatment of mild to intermittent

asthma but is not a part of any treatment guideline. Its approval in 2018 was the cause of much concern in the medical community. Due to this experience, the Council expressed a desire to ensure that FDA approvals for rescue and reversal medication are evidence-based and guideline-driven, given the emergent nature of their use. Council members also noted that in Massachusetts there is a push to change albuterol to OTC, which reinforced the need for a clause that speaks to evidenced-based and guideline-driven approvals. The Council also discussed their concern of supply chain shortages, as occurred with prescription epinephrine in 2018, and therefore included language about ensuring that supply can keep up with demand for rescue and reversal medications.

---

# COUNCIL ON EDUCATION AND WORKFORCE DEVELOPMENT POLICY RECOMMENDATIONS

---

*The Council on Education and Workforce Development is concerned with ASHP professional policies, related to the quality and quantity of pharmacy practitioners. Within the Council's purview are (1) student education, (2) postgraduate education and training, (3) specialization, (4) assessment and maintenance of competence, (5) credentialing, (6) balance between workforce supply and demand, (7) development of technicians, and (8) related matters.*

Kristi Gullickson, *Board Liaison*

## **Council Members**

Joshua Blackwell, *Chair* (Texas)  
Michelle Estevez, *Vice Chair* (Florida)  
Aliyah Cruz (Wisconsin)  
Stacy Dalpoas (North Carolina)  
Sandeep Devabhakthuni (Maryland)  
Johnnie Early II (Florida)  
Glen Gard, *Pharmacy Technician* (Illinois)  
Devon Hess, *Student* (North Carolina)  
Tera Moore (Federal Service)  
Vipul Patel (California)  
Jennifer Robertson (Tennessee)  
Kate Taucher (Colorado)  
Ted Walton (Georgia)  
Sophia Chhay, *Secretary*

---

## **1. Opposition to Pharmacy Jurisprudence Examination Requirement**

- 1 To advocate the removal of a standalone examination of federal or state pharmacy law
- 2 as a requirement for licensure; further,
- 3 To advocate that employers provide initial and ongoing education of the pharmacy
- 4 workforce on pertinent federal and state pharmacy laws; further,
- 5 To acknowledge that it is a professional obligation of a pharmacist to practice in
- 6 compliance with federal and state laws.

### **Rationale**

National pharmacy associations have recently joined in advocacy for a more portable pharmacist license. Pharmacist interstate movement and practice are inhibited by the state-specific nature of the pharmacy jurisprudence examination. The pharmacist's licensing process includes one clinical knowledge exam (the NAPLEX), and in 48 states a jurisprudence exam is required, typically the Multistate Pharmacy Jurisprudence Examination (MPJE) — a 2.5-hour, adaptive, and proctored test. In contrast, physicians take three clinical knowledge exams, and only Texas, Oklahoma, Maine, and Oregon require a jurisprudence exam, which is taken online and is open-resource. Nurses are required to take one clinical knowledge exam (the NCLEX),

and only Texas and Kentucky require a jurisprudence exam, which is also online and open-resource. A [2017 working paper](#) from the National Bureau of Economic Research found that pharmacists ranked among the lowest in terms of between-state migration, at -47%, compared to nurses (+5.5%) and physicians (+33%). While licensure in multiple states has always been almost a prerequisite for practitioners whose systems are in multi-state areas (e.g., VA, MD, DC), the advances in telehealth have made multistate licensure compulsory for many more pharmacists.

Accreditation Council for Pharmacy Education accreditation standards require pharmacy law as part of the curriculum, but student pharmacists may not practice in the state in which they receive their education, and employers should provide training on pertinent federal and state pharmacy laws. Even absent the state law exams, continuing education requirements and professional responsibility require pharmacists to know the laws in the state(s) in which they are licensed.

### **Background**

The Council reviewed licensing requirements across states and professions, the relevance of continued law examination for pharmacists, and potential outcomes of eliminating the MPJE, and determined that ASHP needs a policy advocating the removal of a standalone examination of federal or state pharmacy law as a requirement for licensure. The Council felt eliminating this requirement would allow for greater flexibility regarding interstate movement and practice and align pharmacy with other healthcare professions.

## **2. Pharmacy Technician Education Requirements**

- 1 To recognize that highly trained and skilled pharmacy technicians working in advanced  
2 roles regularly perform complex and critical medication-use procedures, and that a safe  
3 and effective medication-use process depends significantly on the skills, knowledge, and  
4 competency of those pharmacy technicians to perform those tasks; further,
- 5 To reaffirm that all pharmacy technicians should complete an ASHP-accredited training  
6 program, be certified by the Pharmacy Technician Certification Board, and be licensed by  
7 state boards of pharmacy; further,
- 8 To advocate that beyond those requirements, pharmacy technicians working in advanced  
9 roles should complete at a minimum an associate of science degree and demonstrate  
10 ongoing competencies specific to the tasks to be performed; further,
- 11 To advocate that expansion of pharmacy technician duties into expanded, advanced roles  
12 should include consideration of potential risk to patients and that ongoing quality  
13 assurance metrics should be established to assure patient safety.

*Note: This policy would supersede ASHP policy 1203.*

**Rationale**

Pharmacy technician roles have undergone a significant transformation within health systems throughout the years. In today's intricate healthcare landscape, these pharmacy technicians take on advanced responsibilities beyond their traditional duties. These extended roles include managing information systems, sterile product preparation, handling logistics, and implementing cutting-edge technology. According to the 2022 ASHP National Survey, more advanced pharmacy technician roles are emerging, including 340B Drug Pricing Program management, responsibility for USP chapter 797 (USP <797>) compliance, initiation of medication reconciliation, and supervision of other technicians. Pharmacy administrators have also reported a range of functions that health-system technicians perform, including sterile and nonsterile compounding, inventory management, purchasing, hazardous drug handling, controlled substance system management, medication order distribution, supervisory responsibilities, billing and reimbursement, and technician education and training. These advanced roles will require different skills and competencies, and pharmacy technicians should demonstrate competency before being allowed to perform such tasks, which will require additional, task-specific training.

The advancement of the pharmacy technician workforce includes credentialing, licensing, and on-the-job training. Moreover, engaging in formal education such as an associate of science degree equips pharmacy technicians with the necessary skill set to excel in these multifaceted roles, aids human resources departments in assigning an appropriate job code and pay grade, and elevates the pharmacy profession more broadly. Furthermore, other technical personnel in the healthcare sector (e.g., radiology technicians, respiratory therapist, laboratory technicians) are moving towards requiring a minimum of an associate degree and completion of an accredited training program, and aligning pharmacy technician requirements with other professions provides another pathway for enhanced remuneration. In addition, these measures would promote recruitment and retention of the pharmacy technician workforce within hospitals and health systems.

**Background**

The Council reviewed ASHP policy 1203, Qualifications of Pharmacy Technicians in Advanced Roles, as part of the discussion of pharmacy technician formal education requirements for health systems. The Council voted to recommend amending it as follows (underline indicates new text; ~~strikethrough~~ indicates deletions):

To recognize that highly trained and skilled pharmacy technicians working in advanced roles regularly perform complex and critical medication-use procedures, and that a safe and effective medication-use process depends significantly on the skills, knowledge, and competency of those pharmacy technicians to perform those tasks; further,

To reaffirm that all pharmacy technicians should complete an ASHP-accredited training program, be certified by the Pharmacy Technician Certification Board, and be licensed by state boards of pharmacy; further,

To advocate that beyond those requirements, pharmacy technicians working in

advanced roles should ~~have additional training~~ complete at a minimum an associate of science degree and ~~should~~ demonstrate ongoing competencies specific to the tasks to be performed; further,

To advocate that expansion of pharmacy technician duties into expanded, advanced roles should include consideration of potential risk to patients and that ongoing quality assurance metrics should be established to assure patient safety.

### 3. Implications of Artificial Intelligence for Professional Integrity

- 1 To encourage hospitals, health systems, and colleges of pharmacy to adopt policies
- 2 regarding the appropriate use of artificial intelligence and ongoing surveillance of these
- 3 tools.

#### **Rationale**

The rapid advancement of generative artificial intelligence (AI) technologies, such as ChatGPT, has introduced new possibilities and challenges across society, particularly in the realm of education. These technologies appear to offer innovative ways to assist learners, enhance educational experiences, and streamline administrative processes. However, the integration of AI tools raises concerns about academic integrity, plagiarism, and the potential for unethical use that could undermine the educational process. As such, hospitals, health systems, and colleges of pharmacy should adopt policies regarding the appropriate use of AI across the continuum of learning from didactic to experiential and within the clinical learning environment.

AI tools require extensive education and ongoing surveillance about their potential utility and limitations. Ethical and regulatory implications must be considered, as AI is increasingly incorporated into practice, education, and training. Furthermore, pharmacists must be prepared to engage in the development, validation, and implementation of AI to ensure such tools are being leveraged appropriately to support optimal patient care.

#### **Background**

At its Policy Week meeting, the Council reflected on the implications of ChatGPT and AI for academic integrity and guidance to student pharmacists, pharmacy residents, educators, and preceptors. The Council identified a need for ASHP policy on this issue.

### 4. Pharmacy Residency Training

- 1 To continue efforts to increase the number of ASHP-accredited pharmacy residency
- 2 training programs and positions available; further,

- 3 To promote efforts to increase recruitment and retention of residents in ASHP-accredited
- 4 pharmacy residency programs; further,
- 5 To encourage stakeholders to evaluate priority areas within pharmacy for future
- 6 residency training needs.

*Note: This policy would supersede ASHP policy 0917.*

### **Rationale**

ASHP is committed to achieving the goal that “pharmacists who provide direct patient care should have completed an ASHP-accredited residency or have attained comparable skills through practice experience” and advocates that “the completion of an ASHP-accredited postgraduate year one residency be required for all new college or school of pharmacy graduates who will be providing direct patient care.” (ASHP policy position 2027) Furthermore, in the [Practice Advancement Initiative \(PAI\) 2030](#), recommendation B4 states, “Health systems should require completion of ASHP-accredited residency training as a minimum credential for new pharmacist practitioners.” There are opportunities to evaluate recruitment and retention of residents to increase the number who successfully complete residency training programs. In addition, key stakeholders (e.g., colleges of pharmacy, academic medical centers, healthcare organizations, and government agencies) should evaluate priority areas within pharmacy for future training needs, which may include health-system pharmacy administration and leadership, population health management and data analytics, pain and palliative care, medication-use safety and policy, pharmacy informatics, and others.

### **Background**

The Council reviewed ASHP policy 0917, Pharmacy Residency Training, as part of the discussion of pharmacy residency trends. The Council voted to recommend amending it as follows (underscore indicates new text):

To continue efforts to increase the number of ASHP-accredited pharmacy residency training programs and positions available; further,

To promote efforts to increase recruitment and retention of residents in ASHP-accredited pharmacy residency programs; further,

To encourage stakeholders to evaluate priority areas within pharmacy for future residency training needs.

---

# COUNCIL ON PHARMACY MANAGEMENT

## POLICY RECOMMENDATIONS

---

*The Council on Pharmacy Management is concerned with ASHP professional policies related to the leadership and management of pharmacy practice. Within the Council's purview are (1) development and deployment of resources, (2) fostering cost-effective use of medicines, (3) payment for services and products, (4) applications of technology in the medication-use process, (5) efficiency and safety of medication-use systems, (6) continuity of care, and (7) related matters.*

Kim Benner, *Board Liaison*

### **Council Members**

Christy Norman, *Chair* (Georgia)  
Jennifer Miles, *Vice Chair* (Florida)  
Thomas Achey (South Carolina)  
Timmi Anne Boesken, *Pharmacy Technician* (Ohio)  
Elissa Chung, *Student* (Washington)  
Rox Gatia (Michigan)  
Davey Legendre (Georgia)  
Ryan Naseman (Kentucky)  
Rebecca Ohrmund, *Pharmacy Technician* (Illinois)  
Daniel O'Neil (West Virginia)  
Joseph Pinto (New York)  
Ellen Revak (Wisconsin)  
Kate Schaafsma (Wisconsin)  
Tara Vlasimsky (Colorado)  
Jason Wong (Oregon)  
Eric Maroyka, *Secretary*

---

### **1. Documentation of Patient-Care Services in the Permanent Health Record**

- 1 To advocate for public policies that support documentation of patient-care services
- 2 provided by the pharmacy workforce in the permanent patient health record; further,
  
- 3 To promote inclusion of the pharmacy workforce in organization-based credentialing
- 4 and privileging processes and in collaboration with an organization's clinical informatics
- 5 team to ensure accurate and complete documentation of the care provided to patients
- 6 and to validate the impact of patient care provided by the pharmacy workforce on
- 7 patient outcomes and cost of care; further,
  
- 8 To advocate that electronic health records be designed with a common documentation
- 9 space to accommodate all healthcare team members and support the communication
- 10 needs of pharmacy.

*Note: This policy would supersede ASHP policy 1419.*

**Rationale**

Documentation in the patient record is critical for a complete record for patient care and communication among members of the healthcare team. Documentation should be done within an electronic health record (EHR). Organization-based privileging is the process used by a healthcare organization, after evaluating a practitioner's credentials, to assure stakeholders that the healthcare professional has the competencies and experience to provide certain direct patient care services. Privileging grants that individual practitioner permission to deliver those patient care services and document the rendering of those services in the permanent health record. ASHP supports the use of use of post-licensure credentialing, privileging, and competency assessment, in a manner consistent with other healthcare professionals, to practice pharmacy as a direct patient-care practitioner (see ASHP policies 2011, Credentialing and Privileging by Regulators, Payers, and Providers of Collaborative Practice, and 1415, Credentialing, Privileging, and Competency Assessment). Pharmacy technicians, within their scope of practice, have documented activities (e.g., medication history documentation) in the record as part of team-based care documentation. When documenting electronically, use of standardized and coded formats allows for improved measurement of patient outcomes.

**Background**

The Council reviewed ASHP policy 1419, Documentation of Patient-Care Services in the Permanent Health Record, as part of sunset review and voted to recommend amending it as follows (underscore indicates new text; ~~striketrough~~ indicates deletions):

To advocate for public ~~and organizational~~ policies that support pharmacist documentation of patient-care services provided by the pharmacy workforce in the permanent patient health record; further,

To promote inclusion of the pharmacy workforce in organization-based credentialing and privileging processes and in collaboration with an organization's clinical informatics team to ensure accurate and complete documentation of the care provided to patients and to validate the impact of ~~pharmacist~~ patient care provided by the pharmacy workforce on patient outcomes and ~~total~~ cost of care; further,

To advocate that electronic health records be designed with a common documentation space to accommodate all healthcare team members and support the communication needs of pharmacy.

The Council discussed the lengthy first clause in the existing policy and felt advocating for public policies seems reasonable but not so for organizational policies. Promoting incorporation in an organization-based credentialing and privileging process and in collaboration with an organization's clinical informatics team seem practical and actionable. There is some crossover with ASHP policy 2137, Documentation of Pharmacist Patient Care, but that policy focuses more on documentation, billing, and attribution for services rendered. There was some discussion

about a need for advocacy to support documentation of activities by pharmacy technicians within their scope of practice (e.g., medication history documentation) as part of team-based care documentation.

## 2. Supporting High Reliability in Pharmacy Practice

- 1 To state that a commitment to the principles and science of high reliability, with the
- 2 goals of zero medication errors and zero harm, are foundational to pharmacy
- 3 excellence; further,
- 4 To encourage hospitals and health systems to commit to high-reliability principles;
- 5 further,
- 6 To encourage research that informs the creation of best practices in high reliability and
- 7 progress toward implementation of high-reliability principles in all pharmacy services.

### **Rationale**

High reliability is an ongoing process or an organizational frame of mind, not a specific structure. The Agency for Healthcare Research and Quality has outlined practical strategies for healthcare organizations aiming to become highly reliable in their [report](#) of practices employed by hospitals in the High Reliability Organization Learning Network. This mindset is supported by [five characteristic ways of thinking](#): preoccupation with failure; reluctance to simplify explanations for operations, successes, and failures; sensitivity to operations (situation awareness); deference to frontline expertise; and commitment to resilience. High-reliability organizations work to create an environment in which potential problems are anticipated, detected early, and virtually always responded to early enough to prevent catastrophic consequences. The Joint Commission suggests that hospitals and healthcare organizations work to create a strong foundation before they can begin to mature as high-reliability organizations. Such foundational work includes developing a leadership commitment to zero-harm goals, establishing a positive safety culture, and instituting a robust process improvement culture. The Joint Commission also provides metrics and tools for assessing the maturity of an organization's leadership, safety culture, and process improvement culture as preconditions to high reliability. Structured analysis of work processes can eliminate inefficiencies, increase value-added time spent with patients, reduce staff stress, and optimize the use of supplies and other resources. Reliable information technology systems are critical to ensure care quality and improve efficiency in administrative and process measures. ASHP's [PAI 2030](#) includes a recommendation that states: "C9. Pharmacy should employ high-reliability principles when designing and selecting health information technology." Given the rising cost of healthcare and internal competition for finite capital dollars, it is important to identify solutions that will improve

quality and safety while being fiscally responsible. Research is needed to evaluate tasks and processes to identify better approaches that will reduce waste, improve outcomes, and yield significant savings. Continuous improvement on the delivery of high-value care requires healthcare institutions to continually monitor and improve reliability and performance (see ASHP policy 2206, Continuous Performance Improvement).

### **Background**

The Council acknowledged the concept of high reliability is attractive for healthcare due to the complexity of operations and the risk of significant consequences when failures occur. Supporting high reliability in pharmacy practice to improve efficiency and reduce susceptibility to human error can aid in areas such as automating order entry and reducing paperwork; optimizing staffing levels and scheduling; managing equipment and resources; defining care protocols and providing clinical decision support; managing billing and revenue cycles; reducing adverse drug events and duplicate tests; and improving care coordination. The Council suggested that ASHP could help members by promoting knowledge-sharing about high reliability through education and publications and a value analysis through research. Development of a resource to help hospitals and health systems develop a strong foundation before they can begin to mature as high-reliability organizations (HRO) is desired. Some members of the Council stated the ASHP PAI 2030 Self-Assessment Tool addresses aspects of this but an HRO-specific resource would be of value.

### **3. Safe Medication Sourcing, Preparation, and Administration in All Sites of Care**

- 1 To advocate that all sites of care be required to meet the same regulatory standards for
- 2 medication sourcing, preparation, and administration to ensure safety and quality.

*Note: This policy would supersede ASHP policy 1914.*

### **Rationale**

Globally, health spending as a share of the overall economy has been [steadily increasing](#) since the 1980s, as spending growth has outpaced economic growth across all high-income countries, the United States included. This growth is multifactorial but is largely due to advances in medical technologies, including specialty medications; exponential and disparate price increases in the health sector across all markets; and higher demand for services, especially from a growing, aging population ([Commonwealth Fund](#), [Peterson-KFF](#)). Based on data from 2021, the United States spent 18.3% of gross domestic product (GDP) on healthcare, nearly twice as much as the average country in the Organisation for Economic Co-operation and Development ([Peterson-KFF](#), [CMS](#)). Over 2022-2031, average growth in national health expenditures (5.4%) is projected to outpace that of average GDP growth (4.6%), resulting in an

increase in the health spending share of GDP, from 18.3% in 2021 to 19.6% in 2031 (CMS). This increasing cost of healthcare in the United States has motivated stakeholders across the care paradigm to search for strategies to curtail costs. Over the last decade, payers have implemented strategies that fragment providers' comprehensive care management of the patient. These strategies include but are not limited to site-of-care (SOC) optimization, which shifts care away from hospitals, and payer-directed drug distribution models (see ASHP policy 2309, Payer-Directed Drug Distribution Models), which undermine hospitals' patient safety protections and jeopardize patient care. The payers' overarching goal is cost containment, while maintaining access to the prescribed therapy. Cost containment efforts have shifted beyond the traditional pharmacy point-of-sale management intended for self-administered medications under the pharmacy benefit, such as formulary tiering, prior authorization requirements, drug exclusions, and step therapy implementation. These newer payer strategies targeting provider-administered medications under the medical benefit present risks to patient care and safety. Patients are increasingly being required to receive care at lower-cost nonhospital SOCs, rather than at traditional venues, such as hospital outpatient infusion centers. Alternative or nonhospital SOCs include nonhospital-affiliated outpatient infusion centers, physician's offices, ambulatory infusion centers, or patients' homes. Payer-imposed SOC restrictions and policies jeopardize the continuity of care for the patient by introducing incongruent providers and systems (see ASHP policy 2031, Continuity of Care in Insurance Payer Networks). These same policies also create additional logistical challenges for the patient to navigate and can impede timely access to care for patients who require additional special assistance or services, such as access to emergency staff in the event of an adverse reaction. Further, the level of infrastructure required to adequately address regulatory and accreditation requirements focused on quality and safety (e.g., United States Pharmacopeia Chapters 797 and 800, state board of pharmacy regulations, and the standards of accreditors such as The Joint Commission and Det Norske Veritas Healthcare) varies across SOCs, with hospitals carrying the greatest administrative burden and costs. As a result, health systems should collaborate with pharmacy leadership when exploring ways to optimize medication access and appropriate utilization in nonhospital SOCs.

### **Background**

The Council reviewed ASHP policy 1914, Safe Medication Preparation, Compounding, and Administration in All Sites of Care, as part of sunset review and in response to recommendations made by an ASHP member advisory panel and voted to recommend amending it as follows (underline indicates new text; ~~strikethrough~~ indicates deletions):

To advocate that all sites of care be required to meet the same regulatory standards for medication sourcing, preparation, ~~compounding~~, and administration to ensure safety and quality.

The Council discussed opportunities to make the policy recommendation and associated rationale reflective of current practice, healthcare trends, and pharmacy opportunities to ensure optimal patient care. The Council proposed ASHP continue advocacy in opposition to



specific payer strategies that restrict access points, interfere with shared provider-patient decision-making, and jeopardize patient care.

---

## SECTION OF COMMUNITY PHARMACY PRACTITIONERS POLICY RECOMMENDATION

---

*The mission of the ASHP Section of Community Pharmacy Practitioners is to advance community-based pharmacy care by championing safe, equitable, and sustainable patient services. This will be accomplished by promoting practice and operational excellence, inspiring innovation, and fostering meaningful collaborations across the communities we serve.*

Pamela K. Phelps, *Board Liaison*

### **Executive Committee**

Ashley Storvik Boedecker, *Chair* (Wisconsin)  
Courtney Isom (North Carolina)  
Amanda Place (Indiana)  
Jordan Rush (North Carolina)  
Melissa Ortega (Massachusetts)  
Gabrielle Pierce, *Director*

---

### **1. ASHP Statement on the Community Pharmacist’s Role in the Care Continuum**

- 1 To approve the ASHP Statement on the Community Pharmacist’s Role in the Care
- 2 Continuum (Appendix).

## ASHP Statement on the Community Pharmacist’s Role in the Care Continuum

### Position

1 The American Society of Health-System Pharmacists (ASHP) believes that community  
2 pharmacists are skilled clinicians who play an important role in the care continuum as equal,  
3 essential, and valued members of the healthcare team. Community pharmacists provide direct  
4 patient care, advance team-based care, manage patient-centered clinical services, and serve as  
5 leaders within their communities and health systems. Community pharmacists optimize care by  
6 providing educational consultations, medication safety and optimization services, chronic  
7 condition management, patient empowerment, wellness services, care coordination, and other  
8 services.

9 Community pharmacists lead teams that support patient access and safety through  
10 clinical care, medication preparation and dispensing services, regulatory compliance,  
11 operational efficiency, and integration services across settings of care. Further, community  
12 pharmacists lead, manage, and contribute to innovative practices and operations that advance  
13 pharmacy practice and contribute to financial sustainability.

14 The purpose of this statement is to recognize the patient-centered care services  
15 provided by community pharmacists and encourage healthcare leaders to utilize community  
16 pharmacists to the full extent of their expertise by continuing to integrate them across the  
17 continuum of care. This statement will describe current practice of health-system-based  
18 community pharmacy and identify future opportunities for practice advancement, though the  
19 patient-centered core responsibilities described are generalizable to all community pharmacy  
20 practice settings.

21 Community pharmacists should be recognized as medication experts and accountable  
22 partners for optimal health outcomes. ASHP urges community pharmacists and leaders to  
23 advocate for the value of community pharmacists to internal and external stakeholders so their  
24 outcomes-oriented clinical and business expertise is recognized.

### Background

25 Community pharmacies are found across an array of practice areas, including health systems,  
26 traditional retail sites, clinics, independent pharmacies, and integrated within ambulatory care  
27 settings. Community pharmacy ranks among the most frequent patient touch points in  
28 healthcare. More than 90% of Americans live within 5 miles of a pharmacy,<sup>1</sup> and patients visit  
29 their community pharmacist 12 times more frequently than their primary care provider.<sup>2</sup>

30 Patients can benefit from convenient access to healthcare services, and community  
31 pharmacy practitioners are uniquely positioned to take an active role in improving therapeutic  
32 outcomes and providing comprehensive and longitudinal patient-centered care. According to  
33 the Centers for Disease Control and Prevention, nearly half of Americans use at least one  
34 prescription medication each month,<sup>3</sup> and 40% of U.S. adults are managing two or more chronic  
35 conditions.<sup>4</sup> Innovative community pharmacy practices have the potential to significantly  
36 impact outcomes, such as reducing hospital readmission rates, preventing drug-induced harm,  
37 and increasing medication access and adherence.<sup>5-7</sup> Studies have also shown that community  
38 pharmacist-led interventions have a positive impact on a wide range of chronic diseases,  
39 including diabetes, cardiovascular disease, hyperlipidemia, and HIV/AIDS, and have

40 demonstrated a decrease in medical and healthcare costs.<sup>8-10</sup> As the healthcare landscape shifts  
41 toward a value-based framework, there is general agreement on the favorable impact of  
42 community pharmacists in increasing access to care and providing preventive health services.<sup>11-16</sup>

### Core responsibilities

43 **Patient care.** Pharmacists practicing in community settings can both integrate into specific  
44 patient care teams and act as health and wellness advocates in their practice setting. Health-  
45 system-based community pharmacists have uniquely integrated tools, including electronic  
46 health record (EHR) access and communication methods, that facilitate these patient care  
47 activities. Community pharmacists are critical in ensuring that patients in the outpatient setting  
48 receive the medications they need through patient-centered dispensing, while also providing  
49 clinical services that optimize patient care and outcomes. The following encompasses many of  
50 the core clinical responsibilities of community pharmacists.

- 51 **1. Medication utilization reviews:** Patients may routinely seek care from many different  
52 sources and may or may not choose to use a single pharmacy for prescriptions.  
53 Community pharmacists are well positioned to utilize the information from their own  
54 system as well as information obtained from the patient and other pharmacy locations  
55 to compile a comprehensive medication list. Community pharmacists can then use this  
56 information to optimize the patient's medication therapies. Optimization includes, but is  
57 not limited to, utilizing this list to ensure that each medication is an appropriate agent,  
58 prescribed at an appropriate dose and for an appropriate duration. Information  
59 elucidated in this broad-spectrum patient care approach can then be communicated to  
60 the patient's entire healthcare team, reducing the risk for adverse outcomes related to  
61 incomplete understanding of the patient's medication regimen.
- 62 **2. Medication access:** Community pharmacists identify and help resolve medication access  
63 barriers. No other care setting offers the opportunity to routinely identify and overcome  
64 barriers to medication access and appropriate use such as cost, availability, harm  
65 reduction (e.g., providing naloxone), and dosage form modifications. During dispensing  
66 and at the point of sale, community pharmacists have the opportunity to engage the  
67 patient in a discussion regarding affordability of and access to their medications. These  
68 discussions often incorporate a variety of resources, including manufacturer discount  
69 programs, therapeutic interchanges, and use of charitable resources. In some settings,  
70 community pharmacists assist with the prior authorization process as well. Programs  
71 offered by community pharmacies (e.g., medication bedside delivery in acute care  
72 settings and home delivery in ambulatory care settings) can overcome transportation-  
73 related access barriers. These services are part of a broader effort to improve health  
74 equity.
- 75 **3. Comprehensive medication management:** Community pharmacists are trained to  
76 assess and improve medication regimens. Community pharmacists provide cognitive  
77 services to patients that go beyond the dispensing-focused prospective drug utilization  
78 reviews, including comprehensive medication reviews, medication reconciliation, and  
79 chronic disease management. These services can be especially impactful for patients

80 experiencing transitions between acute and ambulatory care with a significant change in  
81 health status. In addition, community pharmacists integrate targeted services such as  
82 medication adherence support, therapeutic optimization, reversal agent access, and  
83 duplicative therapy adjustments into their daily workflow.

84 **4. Point-of-care testing and treatment:** Advances in technology have increased the  
85 availability of testing that can be done outside laboratories, increasing access and  
86 convenience for patients. The advent of direct-to-consumer testing, in addition to CLIA-  
87 waived testing, has spurred a need for healthcare professionals to assist in providing  
88 and/or interpreting test results, formulating next steps, and in some cases initiating  
89 appropriate treatment. Community pharmacists perform and/or interpret point-of-care  
90 testing, including patient-initiated pharmacogenomics testing, and assist patients in  
91 understanding their test results. This service may lead to provision of targeted  
92 treatment for acute infections or recommendations to modify medication regimens that  
93 can be shared with the patient's other healthcare providers. Recognizing that not all  
94 patients with healthcare needs may be able to come to a pharmacy, community health  
95 screening events offer a mechanism for community pharmacists to identify patients in  
96 need of additional assessment and treatment for previously undiagnosed conditions  
97 (e.g., high blood pressure, hyperlipidemia, diabetes, chronic kidney disease).

98 **5. Preventive care provision:** Community pharmacists support patient wellness, both in a  
99 usual or daily setting and when patients can be exposed to new or potentially hazardous  
100 conditions. Wellness care involves preventive interventions (e.g., Medicare Wellness  
101 Visits, health screenings) or travel consultations to prepare travelers for pathogens and  
102 adverse conditions they may encounter abroad. Other preventive and wellness services  
103 may include provision of pre- or post-exposure prophylaxis against HIV infection or oral  
104 contraceptives. In addition, access to many different vaccines with different payer  
105 models is a unique aspect of community pharmacy that has increased patient access to  
106 vaccines. The COVID-19 pandemic highlighted the value of community pharmacists in  
107 ensuring that patients could easily receive recommended vaccines, and rates of routine  
108 immunizations have increased as community pharmacists have expanded vaccination  
109 services.<sup>17,18</sup>

110 **6. Patient and community education:** Community pharmacists have chosen to practice in  
111 a setting that enables them to be a resource for patient education on many different  
112 levels. This role includes not only patient education and counseling regarding specific  
113 medications, over-the-counter products, and complementary and alternative medicines,  
114 but also more comprehensive medication education (e.g., storage, appropriate  
115 administration, safe combinations with other medications or supplements,  
116 recommended disposal). Many community pharmacists and pharmacies offer programs  
117 that provide education and support for specific conditions, such as the Diabetes Self-  
118 Management Education and Support (DSMES) program.<sup>19</sup> Community pharmacists may  
119 be involved in identifying patients who struggle with substance use disorders and can  
120 offer resources and referrals to additional care providers. Pharmacists in this setting can  
121 also serve as educational resources for the broader community during health  
122 screenings, drug take-back events, and community wellness and outreach events. The

123 community pharmacist provides this education in a manner that is tailored to each  
124 patient's educational needs, including language and health-literacy barriers.

125 **7. Medication safety:** Community pharmacists serve as advocates for the safe use of  
126 medications in many ways. The interventions of community pharmacists are highly  
127 impactful on patient safety, whether this is in implementation of the Institute for Safe  
128 Medication Practices Community Pharmacy Action Agenda items,<sup>20</sup> recognition and  
129 mitigation of dangerous drug-drug or drug-disease interactions, or ensuring a patient's  
130 understanding of their medication regimen. Community pharmacists also support safe  
131 use of medications by working on a broader scale within their organizations or locations  
132 to perform continuous quality improvement processes and providing medication safety  
133 resources for other healthcare disciplines. Outreach to the community can raise  
134 awareness of the risks associated with medication misuse and can prevent harm.

135 **Operations.** In addition to core patient care responsibilities, community pharmacists are  
136 responsible for day-to-day operations of the pharmacy and ensuring compliance with state and  
137 federal laws and regulations, as well as accreditation standards. The following encompasses the  
138 core operations of the community pharmacy that the pharmacist manages or supports.

- 139 **1. Team supervision:** Community pharmacists oversee daily operations, including day-to-  
140 day staffing levels and maintaining appropriate pharmacist-to-technician staffing ratios,  
141 developing workstation and workflow expectations and optimizations, and supervising  
142 learners.
- 143 **2. Regulatory compliance:** Community pharmacists ensure compliance with all  
144 regulations, including all state and federal laws, Drug Enforcement Administration  
145 regulations, applicable United States Pharmacopeia (USP) standards (e.g., USP 795),  
146 340B program compliance as applicable, and additional requirements of accreditation  
147 and governing bodies.
- 148 **3. Record-keeping:** Community pharmacists maintain all records (e.g., inventory,  
149 dispensing) in compliance with the Health Insurance Portability and Accountability Act  
150 of 1996, state, and federal regulations.
- 151 **4. Inventory management:** Community pharmacists manage the pharmacy's inventory to  
152 ensure the needs of the patients are served while preventing a surplus of inventory.  
153 Inventory management includes examination of inventory turns, proper security and  
154 storage of medications, and proper inventory management practices as it relates to the  
155 340B program. Additionally, community pharmacists navigate drug shortages.
- 156 **5. Fiscal management:** Community pharmacists manage billing, revenue cycles, inventory  
157 costs, labor, and operational expenses in a fiscally responsible way. Pharmacy leaders  
158 also develop annual budgets and create volume projections for the pharmacy.
- 159 **6. Compounding:** Compounding services can be offered to patients when individualized  
160 pharmaceutical products are not commercially available. If the community pharmacy is  
161 part of a health system, compounded nonsterile preparations available to patients when  
162 admitted to the hospital can be made available in the community pharmacy for  
163 continuation of therapy. Many community pharmacists are able to refer patients to  
164 sterile compounding facilities if needed.

- 165 **7. Program and protocol development:** Community pharmacies offer relevant services  
 166 such as vaccination and meds-to-beds services as applicable. Additional clinical services  
 167 may also be provided, such as medication synchronization, medication adherence  
 168 packaging, and medication delivery programs. Clinical services such as hormonal  
 169 contraception prescribing, smoking cessation, COVID therapeutics, and immunizations  
 170 may be provided through standing orders or collaborative practice agreements as  
 171 allowed by state and federal laws.
- 172 **8. Customer service:** Community pharmacists provide excellent customer service not only  
 173 to patients and customers but also to internal providers and stakeholders in the  
 174 organization. Pharmacists can connect with the patient’s providers to determine  
 175 alternatives in the event of a drug shortage, to navigate insurance restrictions as  
 176 needed, and to accommodate financial restrictions limiting patient access.
- 177 **9. Access to health data:** Community pharmacists utilize the patient’s EHR to ensure  
 178 comprehensive care for patients. Where EHR access is not available, community  
 179 pharmacists may pursue access to health information exchange platforms. Similarly,  
 180 community pharmacies may integrate their dispensing records into the patient’s EHR.
- 181 **10. Health literacy:** Community pharmacists promote health equity by recognizing and  
 182 accommodating the health literacy of their patients. Community pharmacists can  
 183 provide prescription labels and care notes in the patient’s preferred language or in the  
 184 preferred modality for visually or hearing-impaired patients, at an appropriate reading  
 185 level, and utilizing the patient’s preferred name.
- 186 **11. Drug disposal:** With the rise of the opioid epidemic and overdoses, some community  
 187 pharmacies serve as drug disposal sites, allowing patients to safely dispose of unwanted  
 188 medications.

189 **Expanded roles**

190 While the clinical and operational functions described above are fundamental in today’s  
 191 practice for community pharmacists, there are many opportunities to expand how community  
 192 pharmacists demonstrate value in providing direct patient care. Community pharmacists are  
 193 poised to expand their roles due to their accessibility, in-depth knowledge of the medication-  
 194 use process, and ability to quickly pivot and adapt to the changing healthcare landscape (Table  
 195 1).

196 **Table 1. Domains of opportunity for expanded community pharmacist roles.**

<p><b>Impacting Health Outcomes</b></p>	<ul style="list-style-type: none"> <li>• Expand the use of and design new collaborative practice agreements.</li> <li>• Provide access to point-of-care testing for a variety of disease states (e.g., influenza, group A <i>Streptococcus</i>, human immunodeficiency virus, hepatitis C, coronaviruses, oral contraceptives, and chronic diseases).</li> <li>• Engage patients in health and wellness initiatives (e.g., smoking cessation, weight management, asthma, chronic heart failure,</li> </ul>
---	--

	<p>chronic obstructive pulmonary disease, diabetes, hyperlipidemia, hypertension, anticoagulation, medication adherence).</p> <ul style="list-style-type: none"> <li>Promote preventive care such as establishing a primary provider and health screenings.</li> </ul>
<b>Education</b>	<ul style="list-style-type: none"> <li>Incorporate learners at all levels by expanding opportunities for clinical rotation experiences and residency programs.</li> <li>Continue to support technician education and advancement initiatives.</li> <li>Encourage practitioners to meet the needs of evolving patient populations through gaining advanced clinical knowledge.</li> </ul>
<b>Health Equity</b>	<ul style="list-style-type: none"> <li>Overcome barriers that cause health inequities in patient care.</li> </ul>
<b>Technology</b>	<ul style="list-style-type: none"> <li>Identify how technology can be leveraged to create operational efficiencies in practice.</li> <li>Expand or partner in developing precision medicine and pharmacogenomics opportunities.</li> <li>Develop and evaluate artificial intelligence and cognitive support tools.</li> <li>Support patients in their wellness journey by use of technology such as health apps, wearable devices, and other tools.</li> </ul>
<b>Patient-centric Models</b>	<ul style="list-style-type: none"> <li>Perform ongoing evaluations of the patient-centered medical home model or hospital-at-home services.</li> <li>Leverage technology to offer clinical services through in-person care, health applications, patient portals, and telehealth options.</li> </ul>
<b>Innovation</b>	<ul style="list-style-type: none"> <li>Collaborate with clinicians to increase pharmacy-offered clinical services to alleviate provider burnout.</li> <li>Enhance the patient experience by offering a team-based approach to the continuum of care.</li> <li>Identify opportunities that not only advance patient care but also increase the pharmacy department's financial contribution to the organization.</li> <li>Continue to advocate for billing avenues and recognition of services by payers.</li> </ul>
<b>Public Health</b>	<ul style="list-style-type: none"> <li>Evaluate and investigate community health issues.</li> <li>Educate the community about public health.</li> <li>Engage in organizational efforts to prepare and respond to emergencies which may include leadership roles on emergency managements teams.</li> <li>Develop and implement programs related to medication and vaccine access.</li> <li>Offer wellness, disease prevention, and treatment services (e.g. immunizations, antimicrobial stewardship, HIV prevention,</li> </ul>

	<p>diabetes prevention programs, hormonal contraception education, substance abuse prevention/treatment).</p> <ul style="list-style-type: none"> <li>• Support disease surveillance and monitoring initiatives (e.g. antiviral dispensing rates for infectious disease data trending, asthma inhaler use and environmental or air quality concerns)</li> </ul>
<b>Population Health</b>	<ul style="list-style-type: none"> <li>• Participate in the development of metrics to identify and care for specific patient populations.</li> <li>• Promote vaccine confidence within communities.</li> <li>• Extend services to virtual care and video visits.</li> <li>• Partner with clinicians, health plans, and health system leaders to understand value-based payment models and associated metrics.</li> <li>• Ensure effective chronic disease management that includes evidence-based medication optimization and monitoring.</li> <li>• Identify associated quality measures and develop initiatives to support or address open care gaps (e.g., order routine lab testing, ensure appropriate statin usage, and encourage eye exams for patients with diabetes).</li> <li>• Promote medication adherence and support initiatives to improve medication access.</li> <li>• Promote health equity by identifying and addressing Social Determinants of Health (SDOH) to reduce health care disparities.</li> <li>• Participate in transition of care services to reduce readmissions in target patient populations.</li> <li>• Support and promote cost-effective medication usage to control cost of healthcare</li> </ul>
<b>Research</b>	<ul style="list-style-type: none"> <li>• Pursue opportunities to participate in investigational drug research, including dispensing and counseling for commercial and investigational drugs within clinical trials.</li> <li>• Contribute to the body of literature by sharing results of outcomes-based research.</li> <li>• Encourage patient and clinician participation in research.</li> <li>• Contribute to research through data collection.</li> </ul>

197 To be successful in the development of expanded roles for community pharmacy practitioners,  
 198 all pharmacy team members must be trailblazers, early adopters of practice change, and  
 199 actively advocating for pharmacy practice advancement.

### Practice challenges

200 Although community pharmacists are well equipped to improve therapeutic outcomes and  
 201 patient care, practice challenges exist. Declining reimbursements to pharmacies by insurance  
 202 plans have become increasingly problematic. Since the establishment of performance-based  
 203 pharmacy contracts by Medicare Part D plans in 2012, price concessions charged to pharmacies

204 by insurance plans and pharmacy benefit managers increased 170%.<sup>21</sup> Further, limited payment  
205 of pharmacists for clinical services has led to serious financial strains on community  
206 pharmacies, forcing closures, and has resulted in lack of access to community pharmacy  
207 services in rural settings. Studies showed that 1 in 8 pharmacies closed between 2009 and  
208 2015, a statistic that disproportionately affected independent pharmacies and low-income  
209 neighborhoods.<sup>22</sup>

210 The lack of ready access to a pharmacy, a phenomenon labeled “pharmacy deserts,” is a  
211 persistent practice challenge. In rural areas, travel time to the nearest pharmacy may hinder  
212 access. And although more than 90% of Americans live within 5 miles of a pharmacy, proximity  
213 does not guarantee access.<sup>23</sup> Patients may still be stymied by lack of public transportation,  
214 limited pharmacy hours, or mobility issues. To promote health equity, patients should be  
215 provided easy access to community pharmacy services. Telepharmacy is one option that has  
216 been shown to increase patient access to pharmacy services.<sup>24</sup>

217 Limited revenue for community pharmacies has further been aggravated by a changing  
218 economy and workforce. In a recent report by the National Community Pharmacy Association,  
219 93% of community pharmacists noted their business was affected by inflation. Concurrently,  
220 80% of respondents indicated being affected by supply chain shortages, and more than three  
221 quarters of community pharmacists have experienced staffing shortages recently.<sup>25</sup>

222 Access to patients' health information also presents a challenge to optimal care, as  
223 community pharmacies often do not have access to the patient's complete electronic medical  
224 record. To combat this, community pharmacies should pursue access to health information  
225 exchange platforms. Similarly, community pharmacy dispensing records should be accessible in  
226 the EHR.

227 Staffing shortages in the community pharmacy and financial strains impact care. Despite  
228 increasing evidence favoring community pharmacist involvement in advanced clinical services,  
229 uptake is slow. The 2019 National Pharmacist Workforce Study<sup>26</sup> found that services such as  
230 vaccinations, medication assistance programs, medication therapy management, and  
231 medication synchronization are offered in most community pharmacy sites. However, only 43%  
232 of community pharmacy respondents indicated that they provide comprehensive medication  
233 management, 25%, opioid deprescribing; 24%, disease state management; 20%, point-of-care  
234 testing; 19%, injection administration; and 4%, pharmacogenomics testing. The study also  
235 identified high workload and inadequate staffing as the top two stressors for pharmacists.

236 The public perception of the range of roles of pharmacists may also pose a challenge.  
237 Though pharmacists provide a myriad of clinical and operational services, patients are often  
238 unaware of the extent of the role of the pharmacist in the medication-use process.<sup>27</sup> Patients  
239 visiting their local community pharmacy may not see the clinical decisions that pharmacists  
240 make daily and may not be aware that pharmacists act as a part of their interprofessional care  
241 team.

### **Leveraging pharmacy technicians**

242 As community pharmacists face increased workload demands and limited time, advanced  
243 pharmacy technicians can be utilized as pharmacist extenders, furthering pharmacy practice  
244 and patient care.<sup>28-30</sup>

245 Traditional community pharmacy technician roles include entering prescriptions into the  
 246 pharmacy dispensing system, counting medications, compounding, managing inventory, dealing  
 247 with billing issues and insurance, and providing customer service at the point of sale. Limiting  
 248 pharmacy technicians to only these roles does not utilize their full potential.<sup>29</sup> An advanced  
 249 pharmacy technician is an individual who has responsibilities and tasks that go beyond the  
 250 traditional duties of a standard pharmacy technician and requires a higher level of training,  
 251 expertise, and often additional certifications. Nontraditional and advanced roles for pharmacy  
 252 technicians can contribute to the overall impact of community pharmacy practice in patient  
 253 care.<sup>28,31-34</sup> Some of these advanced pharmacy technician responsibilities are listed in Table 2.  
 254 The role of pharmacy technicians is variable depending on the laws of each state and  
 255 responsibilities highlighted may not encompass all technicians.

256 **Table 2. Advanced pharmacy technician responsibilities in community pharmacy.**

Patient care responsibilities	Operational responsibilities
<ul style="list-style-type: none"> <li>• Administer immunizations and promote vaccine confidence.</li> <li>• Collect medication history.</li> <li>• Conduct point-of-care tests.</li> <li>• Identify and resolve barriers to medication access or care.</li> <li>• Enroll patients in patient assistance programs.</li> <li>• Serve as patient advocate.</li> <li>• Assist with patient adherence efforts.</li> <li>• Leverage patient relationships to promote preventive and essential health services.</li> <li>• Obtain additional training (e.g., as a community health worker).</li> </ul>	<ul style="list-style-type: none"> <li>• Engage in technician product verification and tech-check-tech programs.</li> <li>• Coordinate 340B activities.</li> <li>• Manage billing, prior authorizations, and financial affairs.</li> <li>• Manage pharmacist schedules and consultations.</li> <li>• Supervise ancillary staff.</li> <li>• Provide peer education and training.</li> <li>• Gather data and generate metrics and reports.</li> <li>• Oversee medication inventory and surveillance.</li> <li>• Assist in pharmacy workflow optimization.</li> <li>• Contribute to continuous quality improvement and patient safety efforts.</li> </ul>

257 By redesigning the pharmacy workflow and using pharmacy technicians as pharmacist  
 258 extenders, community pharmacies can optimize the pharmacists’ accessibility and provide  
 259 quality healthcare to their communities. Community pharmacists and leaders should support  
 260 advanced community pharmacy technician training opportunities, which will allow pharmacy  
 261 technicians to elevate their practice and contribute to advanced roles.

**Professional obligations of community pharmacists**

262 Community pharmacists have a long-standing commitment to make a tremendous, positive  
 263 impact in patient care and the communities they serve. To overcome the financial and

264 workforce challenges currently impacting care, community pharmacists have a professional  
265 obligation to be advocates for the pharmacy profession and their practice in the following ways.

266 Community pharmacists should

- 267 • Engage in advocacy efforts, through state and national partners, to advance and protect  
268 the interests of patient care and the pharmacy profession.
- 269 • Continue to pursue educational and training opportunities that further their clinical and  
270 professional skills.
- 271 • Seek opportunities to engage in advanced roles that optimize patient outcomes, patient  
272 safety, operational efficiencies, and fiscal health for their patients and organizations.
- 273 • Commit to being innovators, who adapt to and lead contemporary models of care.
- 274 • Act as positive and ethical role models for their patients, colleagues, and the  
275 community.
- 276 • Serve as mentors and educators for student pharmacists and pharmacy residents,  
277 contributing to succession planning for a diverse and healthy workforce.
- 278 • Encourage the advancement and recognition of pharmacy technician partners.
- 279 • Participate in research evaluating the services that they provide.

### Conclusion

280 The role of community pharmacists has evolved significantly. Pharmacists in community-based  
281 settings are operational leaders for the financial sustainability of healthcare institutions as well  
282 as valuable clinicians in providing comprehensive management of patient's medication therapy  
283 in collaboration with other healthcare colleagues.

### Authors

#### **Melissa Ortega, PharmD, MS, FASHP\***

System Vice President, Ambulatory Pharmacy Services  
Tufts Medicine  
Boston, MA

#### **Courtney Isom, PharmD, BCACP, CPP\***

Pharmacy Administrative Coordinator  
Cone Health Community Pharmacy at Wendover Medical Center  
Greensboro, NC

#### **Amanda Place, PharmD, BCACP\***

Ambulatory Care Clinical Pharmacy Specialist  
Ascension St. Vincent Joshua Max Simon Primary Care Center  
Indianapolis, IN

#### **Jordan Rush, Pharm D, MS\***

Director, System Retail and Outpatient Pharmacy  
UNC Health  
Chapel Hill, NC

**Ashley Storvick Boedecker, PharmD, MBA\***

Director of Pharmacy, Ambulatory Service  
Advocate Aurora Health  
Milwaukee, WI

**Georgia G. Luchen, PharmD**

Director of Digital Health and Data  
ASHP Innovation Center  
*(At the time of statement authorship was serving as the Director, Member Relations for the Section of Community Pharmacy Practitioners)*  
ASHP  
Bethesda, MD

**Gabrielle Pierce, PharmD, MBA**

Director, Member Relations  
Section of Community Pharmacy Practitioners and Section of Specialty Pharmacy Practitioners  
ASHP  
Bethesda, MD

\*Member of the ASHP Section of Community Pharmacy Practitioners Executive Committee 2022-2023.

**Disclosures**

The authors have declared no potential conflicts of interest.

**Additional information**

Developed through the ASHP Section of Community Pharmacy Practitioners and approved by the ASHP Board of Directors on March 1, 2024, and by the ASHP House of Delegates on MONTH XX, 2023.

**References**

1. Berenbrok LA, Tang S, Gabriel N et al. Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis. *J Am Pharm Assoc.* 2022; 62:1816-1822.
2. Haddock R. The expanding role of today's community pharmacists. <https://www.fdsrx.com/expanding-role-community-pharmacists> (accessed 2023 Jan 31).
3. Centers for Disease Control and Prevention. FASTSTATS - therapeutic drug use (December 2022). <http://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm> (accessed 2023 Jan 31).
4. Centers for Disease Control and Prevention. Chronic Diseases in America (December 2022). <https://www.cdc.gov/chronicdisease/resources/infographic/chronic-diseases.htm> (accessed 2023 Jan 31).
5. Rajiah K, Sivarasa S, Maharajan MK. Impact of pharmacists' interventions and patients' decision on health outcomes in terms of medication adherence and quality use of

- medicines among patients attending community pharmacies: a systematic review. *Int J Environ Res Public Health*. 2021; 18(9):4392.
6. Shaver A, Morano M, Pogodzinski J et al. Impact of a community pharmacy transitions-of-care program on 30-day readmission. *J Am Pharm Assoc*. 2019; 59(2):202-209.
  7. Armour CL, Smith L, Krass I. Community pharmacy, disease state management, and adherence to medication: a review. *Dis Manag Health Out*. 2008; 16(4):245-54.
  8. Newman TV, San-Juan-Rodriguez A, Parekh N et al. Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: an umbrella review. *Res Social Adm Pharm*. 2020; 16(9):1155-1165.
  9. Armor BL, Britton ML, Dennis VC et al. A review of pharmacist contributions to diabetes care in the United States. *J Pharm Pract*. 2010; 23(3):250-64.
  10. Hemberg N, Huggins D, Michaels N et al. Innovative community pharmacy practice models in North Carolina. *NC Med J*. 2017; 78(3):198-201.
  11. Ayorinde AA, Porteous T, Sharma P. Screening for major diseases in community pharmacies: a systematic review. *Int J Pharm Pract*. 2013; 21(6):349-61.
  12. Brown TJ, Todd A, O'Malley C et al. Community pharmacy delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. *BMJ Open*. 2016; 6(2):e009828.
  13. Blalock SJ, Roberts AW, Lauffenburger JC et al. The effect of community pharmacy-based interventions on patient health outcomes: a systematic review. *Med Care Res Rev*. 2013; 70(3):235-66.
  14. Ifeanyi Chiazor E, Evans M, van Woerden H et al. A systematic review of community pharmacists' interventions in reducing major risk factors for cardiovascular disease. *Value Health Reg Issues*. 2015; 7:9-21.
  15. San-Juan-Rodriguez A, Newman TV, Hernandez I et al. Impact of community pharmacist-provided preventive services on clinical, utilization, and economic outcomes: an umbrella review. *Prev Med*. 2018; 115:145-55.
  16. Altowaijri A, Phillips CJ, Fitzsimmons D. A systematic review of the clinical and economic effectiveness of clinical pharmacist intervention in secondary prevention of cardiovascular disease. *J Manag Care Pharm*. 2013;19(5):408-16.
  17. Isenor JE, Edwards NT, Alia TA et al. Impact of pharmacists as immunizers on vaccination rates: a systematic review and meta-analysis. *Vaccine*. 2016; 34:5708-5723. doi: 10.1016/j.vaccine.2016.08.085.
  18. Grabenstein JD. Essential services: quantifying the contributions of America's pharmacists in COVID-19 clinical interventions. *J Am Pharm Assoc*. 2022; 62:1929-1945.
  19. Centers for Disease Control and Prevention. Diabetes Self-Management Education and Support (DSMES) Toolkit. <https://www.cdc.gov/diabetes/dsmes-toolkit/index.html> (accessed 2024 Jan 17).
  20. Institute for Safe Medication Practices (ISMP). ISMP List of High-Alert Medications in Community/Ambulatory Care Settings. ISMP; 2021. <https://www.ismp.org/recommendations/high-alert-medications-community-ambulatory-list> (accessed 2023 May 11)

21. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency. 87 Fed. Reg. 27704 (May 9, 2022). <https://www.federalregister.gov/d/2022-09375> (accessed 2023 May 11).
22. Guadamuz JS, Alexander GC, Zenk SN et al. Assessment of Pharmacy Closures in the United States From 2009 Through 2015. *JAMA Intern Med.* 2020;1;180(1):157-160.
23. Ying X, Kahn P, Mathis WS. Pharmacy deserts: more than where pharmacies are. *J Am Pharm Assoc.* 2022; 62:1875-9.
24. Urick BY, Adams JK, Bruce MR. State Telepharmacy Policies and Pharmacy Deserts. *JAMA Netw Open.* 2023; 6:e2328810. doi:10.1001/jamanetworkopen.2023.28810.
25. National Community Pharmacists Association. Survey of community pharmacy economic pressures 2022 report. <https://ncpa.org/sites/default/files/2022-08/Pharmacy%20economic%20health%20survey%20AUG%2022.pdf> (accessed 2023 Jan 31).
26. Doucette WR, Mott DA, Kreling DH et al. National Pharmacist Workforce Study 2019. [https://www.aacp.org/sites/default/files/2020-03/2019\\_NPWS\\_Final\\_Report.pdf](https://www.aacp.org/sites/default/files/2020-03/2019_NPWS_Final_Report.pdf) (accessed 2023 May 11).
27. Schommer JC and Gaither CA. A segmentation analysis for pharmacists' and patients' views of pharmacist roles. *Res Soc Admin Pharm.* 2014;10(3):508-528.
28. Hohmeier KC. Pharmacy technicians: how advanced skills are moving the industry forward. <https://www.pharmacytimes.com/view/pharmacy-technicians-how-advanced-skills-are-moving-the-industry-forward> (accessed 2022 Oct 13).
29. Koehler T, Velthuis F, Helmich E et al. Implementing the pharmacy technician role in existing pharmacy settings: stakeholders views of barriers and facilitators. *Res Soc Admin Pharm.* 2022; 18(10):3814-3820.
30. National Association of Chain Drug Stores. Pitt Pharmacy: Pharmacy technician role expansion: an evidence-based position paper (2018). <https://www.nacds.org/pdfs/pharmacy/2020/Pharmacy-Technician-Expansion-Position-Paper.pdf> (accessed 2022 October 13).
31. Taylor B, Mehta B. The community pharmacy technician's role in the changing pharmacy practice space. *Innov Pharm.* 2020; 11(2):11.
32. Mattingly AN, Mattingly II TJ. Advancing the role of the pharmacy technician: a systematic review. *J Am Pharm Assoc.* 2018; 58:94-108.
33. PowerPak. The Expanding Role of the Pharmacy Technician-MTM and Vaccination Support. <https://www.powerpak.com/course/content/114117> (accessed 2022 October 13).
34. McKeirnan KC, McDonough RP. Transforming pharmacy practice: advancing the role of technicians. *Pharmacy Today.* June 2018. Available at: <https://www.pharmacytoday.org/action/showPdf?pii=S1042-0991%2818%2930793-X> (accessed 2022 October 13).

# House of Delegates

---

## REPORT OF THE COMMITTEE ON RESOLUTIONS

June 9, 2024

Portland, Oregon

Nishaminy Kasbekar, Chair  
Leigh A. Briscoe-Dwyer, Vice Chair  
Paul C. Walker  
Christene M. Jolowsky  
Kimberley W. Benner  
Melanie A. Dodd  
Kristine K. Gullickson  
Vivian Bradley Johnson  
Pamela K. Phelps  
Vickie L. Powell  
Jennifer E. Tryon  
Paul W. Abramowitz, Chief Executive Officer

Article 7.2.2.1 of the ASHP Rules of Procedure for the House of Delegates states:

Resolutions not voluntarily withdrawn by the submitter that meet the requirements of the governing documents shall be presented to the House of Delegates by the Committee on Resolutions at the first meeting and acted upon at the second meeting. They shall be submitted to delegates with one of the following recommendations: (a) recommend adoption, (b) do not recommend adoption, (c) recommend referral for further study, or (d) presented with no recommendation of the Committee on Resolutions.

Action by the House of Delegates shall be on the substance of the resolutions and not on the recommendation of the Committee on Resolutions.

Pursuant to the above article, the Committee on Resolutions presents the attached resolution (Appendix A) to the House of Delegates. The recommendation of the Committee is to **refer the resolution to the Council on Pharmacy Management for further study**. The Committee noted that the Council on Pharmacy Management is slated to perform a sunset review of ASHP policy 2042, Controlled Substances Diversion Prevention (Appendix B), in September. The Committee expressed support for the substance of the resolution, noting that it reflects best practices ASHP includes in the [ASHP Guidelines on Preventing Diversion of Controlled Substances](#) and the [ASHP Statement on the Pharmacist's Role in Substance Abuse Prevention, Education, and Assistance](#), but agreed that incorporating the concepts of the resolution into a revision of policy 2042 would provide necessary context. The Committee reiterated ASHP's support, as expressed in the guidelines and statement, for distinguishing between diversion to support a substance use disorder or for financial gain and for a process to support recovery for such employees that includes assessment of an employee's ability to return to patient care. The Committee emphasized, however, that an empathetic approach to employee substance use disorders must be balanced with other priorities, including patient safety, legal and regulatory compliance, and employee protection, as outlined in the fourth clause of policy 2042 (i.e., controlled substances diversion prevention programs should "support a safe patient-care environment, protect co-workers, and discourage controlled substances diversion.") The Committee concluded that the ASHP policy committee process, with its studied reflection and multiple layers of review, would be the best way to arrive at policy that expresses a nuanced stance on these complex and competing issues.

Delegates are reminded that they are voting on the substance of the resolution, which is approval of the motion as follows:

To advocate that hospitals adopt alternatives to discipline programs for healthcare workers (HCWs) who have diverted controlled substances to support their own substance use disorder; further,

To encourage state licensing boards to provide structured rehabilitation programs for such HCWs that lead to return to practice upon successful completion.

The options for House action on the resolution, to be taken at the second meeting, are to (a) approve the motion; (b) defeat the motion; (c) refer the motion for further study by a committee or task force to be determined by the Board of Directors (**the option recommended by the Committee on Resolutions**); or (d) amend the resolution, which would then require due consideration by the Board of Directors at its next meeting in September.

## Resolution for the 2024 ASHP House of Delegates: Alternatives to Discipline Programs in Drug Diversion

**Submitted by:**

Samantha Roberts

Woodstock, GA

elysha.roberts@emoryhealthcare.org

Christy Norman

Decatur, GA

christy.norman@emoryhealthcare.org

**Subject: Alternatives to Discipline Programs in Drug Diversion**

**Received: February 28, 2024**

**Motion**

To advocate that hospitals adopt alternatives to discipline programs for healthcare workers (HCWs) who have diverted controlled substances to support their own substance use disorder; further,

To encourage state licensing boards to provide structured rehabilitation programs for such HCWs that lead to return to practice upon successful completion.

**Background**

At least one in every 100 healthcare workers (HCWs) is estimated to have diverted medication.<sup>1</sup> Because most drug diversion goes undetected, the true number is likely much higher. Moreover, an estimated 10-15% of HCWs will misuse substances within their career.<sup>2</sup> Due to the physical demands of the job, increasing levels of burnout, and ease of access to controlled substances (CS), occupational risk factors contribute to substance misuse in the healthcare setting. Substance use disorders are formally recognized by The Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition, with decades of research linking these disorders to changes in brain chemistry.<sup>3</sup>

Historically, the stigma associated with such diagnoses and the fear of license revocation have prevented HCWs from seeking treatment. Many hospitals and health systems have begun to offer confidential faculty and staff assistance programs (FSAPs); however, these resources continue to be underutilized. Even after diverters have been caught, many will not admit to any wrongdoing for fear of loss of employment. These situations can lead to the diverter resigning and seeking employment elsewhere. Typically, the behavior will continue, putting patients and co-workers at risk for safety events. Furthermore, the risk of suicide is high after personnel are confronted about diversion.

To prevent adverse outcomes, HCWs need to retain insurance and access treatment on a leave of absence or disability basis, with return to work after completing state board-

mandated protocols. Since 1991, ASHP has supported employer-sponsored drug programs that promote the recovery of impaired individuals.<sup>4</sup> Less punitive approaches are more recently recommended in the 2022 [ASHP Guidelines on Preventing Diversion of Controlled Substances](#), which state that “sanctions should take into account whether the HCW is supporting his or her own substance use disorder (or that of an associate) or there has been theft of CS for sale and financial gain.” The guidelines further recommend that when an HCW is diverting to support a substance use disorder, the diversion “should be referred to applicable licensing boards, and the HCW should be referred to a substance abuse program.” The guidelines encourage healthcare organizations to “establish a process to support recovery for HCWs who are diverting CS for an active substance abuse problem (i.e., an employee assistance program process, which may include mandatory program referral, reporting to the relevant state board or professional assistance program, and a contract for the HCW’s return to work).”<sup>5</sup> A 2021 ASHP survey found that 83% of surveyed healthcare organizations supported employee substance use recovery programs, and 65% had return-to-work policies for employees who wanted to reenter the workforce following recovery.<sup>6</sup>

State boards of pharmacy have embraced employee substance use recovery programs and return-to-work policies. As of 2017, 46 states had programs for assisting pharmacy professionals.<sup>7</sup> Given their essential role in enabling HCWs to return to practice, ASHP encourages all state bodies responsible for licensing HCWs to provide structured rehabilitation programs for HCWs with substance use disorders that lead to return to practice upon successful completion.

## References

1. Protenus. 2023 Diversion Digest. Accessed February 8, 2024. [https://protenus.com/hubfs/Drug%20Diversion%20Digest/DiversionDigest\\_Diversion\\_2023\\_Protenus.pdf](https://protenus.com/hubfs/Drug%20Diversion%20Digest/DiversionDigest_Diversion_2023_Protenus.pdf).
2. Hazelden Betty Ford Foundation. Research Update. Health Care Professionals: Addiction and Treatment. Center City, MN: Butler Center for Research. Accessed February 8, 2024. <https://www.hazeldenbettyford.org>
3. American Psychiatric Association, DSM-5 Task Force. (2013). *Diagnostic and statistical manual of mental disorders: DSM-5* (5th ed.). American Psychiatric Publishing, Inc. [doi.org/10.1176/appi.books.9780890425596](https://doi.org/10.1176/appi.books.9780890425596)
4. American Society of Hospital Pharmacists [ASHP]. ASHP policy position 1903; cited in the ASHP Statement on the Pharmacist’s Role in Substance Abuse Prevention, Education, and Assistance. *Am J Health-Syst Pharm*. 1998; 55: 1721-1724.
5. Clark J, Fera T, Fortier C et al. ASHP guidelines on preventing diversion of controlled substances. *Am J Health-Syst Pharmacy*. 2022; 79(24):2279-2306. [doi:10.1093/ajhp/zxac246](https://doi.org/10.1093/ajhp/zxac246)
6. Fortier CR. National Hospital and Health-System Controlled Substances Drug Diversion Prevention & Surveillance Program Assessment Survey — 2021. *Am J Health-Syst Pharm*. 2024; 81:137-145. [doi:10.1093/ajhp/zxad222](https://doi.org/10.1093/ajhp/zxad222)
7. Light KE, Goodner K, Seaton VA et al. State programs assisting pharmacy professionals with substance use disorders. *J Am Pharm Assoc* (2003). 2017; 57(6):704-710. [doi:10.1016/j.japh.2017.07.002](https://doi.org/10.1016/j.japh.2017.07.002)

**Suggested Outcome**

Adoption of this resolution would support changes in health systems' human resources approach to mandatory termination upon discovery of a diversion by a healthcare worker. Such changes would allow for thoughtful deliberation of commensurate consequences. Adoption of the resolution would also encourage state licensing boards to provide rehabilitation-based avenues for return to work for HCWs affected by substance use disorder.

**ASHP Policy 2042, Controlled Substances Diversion Prevention**

*Source: Council on Pharmacy Management*

To enhance awareness by the pharmacy workforce, other healthcare workers, and the public of the potential threats to the public and patient care and safety presented by diversion of controlled substances; further,

To encourage healthcare organizations to develop controlled substances diversion prevention programs (CSDPPs) and supporting policies that delineate the core administrative elements and system- and provider-level controls needed to deter diversion of controlled substances at all stages of medication use; further,

To encourage healthcare organizations to address in their CSDPPs the roles, responsibilities, and oversight of all workers who may have access to controlled substances to ensure compliance with applicable laws and scopes of practice; further,

To encourage healthcare organizations to ensure that all healthcare workers are appropriately screened for substance abuse prior to initial employment and that surveillance, auditing, and monitoring are conducted on an ongoing basis to support a safe patient-care environment, protect co-workers, and discourage controlled substances diversion; further,

To advocate that pharmacists take principal roles in collaborative, interdisciplinary efforts by organizations of healthcare professionals, patient advocacy organizations, and regulatory authorities to develop and promote best practices for preventing drug diversion and appropriately using controlled substances to optimize and ensure patient access and therapeutic outcomes; further,

To advocate that the Drug Enforcement Administration and other regulatory authorities interpret and enforce laws, rules, and regulations to support patient access to appropriate therapies, minimize burdens on pharmacy practice, and provide reasonable safeguards against fraud, misuse, abuse, and diversion of controlled substances.

*This policy supersedes ASHP policies 1614 and 1709.*

# House of Delegates

---

## Important Dates for Proposed Policy Amendments, May-June 2024

**May 6:** Chair's email message to delegates sent urging those interested in amending policy recommendations to complete a survey (email includes list of policy recommendations going to May virtual House).

**May 15:** Deadline for delegates to submit contact info and proposed amending language through survey.

**May 16-17:** Emails (one for each policy for which amendments are proposed) will be sent to amending delegates (identified through the survey and ASHP Connect posts), council/section/forum chairs and vice chairs, and council secretaries and section or forum directors.

**May 28:** Target date for amending delegates to develop consensus amending language.

**May 29:** Target date for posting proposed amending language on ASHP Connect and submitting consensus amending language through the amending language form on the [Calls, Forms, and Rosters](#) page of the House of Delegates website.

**June 7:** Deadline for submitting consensus amending language through the amending language form on the [Calls, Forms, and Rosters](#) page of the House of Delegates website for consideration at the First Delegate Caucus.

# House of Delegates



## 2024 ASHP HOUSE OF DELEGATES MEETINGS AT A GLANCE

### Oregon Convention Center Portland, Oregon

- ◆ [House of Delegates Registration](#)  
Saturday, June 8, 10:30 a.m. – 5:45 p.m.  
Sunday, June 9, 7:00 a.m. – 11:00 a.m.  
(After then, delegates may register in the Executive Office, Room A104, Level 1)  
**Pre-Function C**  
Level 1
- ◆ [Open Forum for Members](#)  
Saturday, June 8, 2:30 – 4:30 p.m.  
**Room C123**  
Level 1
- ◆ [Delegate Primer on HOD Processes](#)  
(For all delegates and alternate delegates)  
Saturday, June 8, 4:30 – 5:30 p.m.  
**Room B114**  
Level 1
- ◆ [First Delegate Caucus](#)  
Sunday, June 9, 9:30 – 11:30 a.m.  
**Room C123**  
Level 1
- ◆ [Second Delegate Caucus](#)  
Tuesday, June 11, 12:15 – 2:00 p.m.  
**Room C123**  
Level 1
- ◆ [Other Caucuses](#)  
Small and Rural Hospital Caucus, Sunday, June 9, 7:30 – 8:30 a.m.  
Federal Pharmacist Caucus, Sunday, June 9, 8:30 – 9:30 a.m.  
**Room C121**  
Level 1
- ◆ [First House of Delegates Meeting](#)  
Sunday, June 9, 1:00 – 5:00 p.m.  
**Exhibit Hall A**  
Level 1
- ◆ [Meet the Candidates](#)  
Monday, June 10, 12:15 – 1:45 p.m.  
**Room C123**  
Level 1
- ◆ [Delegate Reception](#)  
Monday, June 10, 5:30 – 6:30 p.m.  
**Regency Ballroom B**  
Level 2  
Hyatt Regency
- ◆ [Second House of Delegates Meeting](#)  
Tuesday, June 11, 4:00 – 6:00 p.m.  
**Exhibit Hall A**  
Level 1

# House of Delegates

## DRAFT AGENDA

ASHP House of Delegates  
Portland, Oregon

Presiding – Melanie A. Dodd  
Chair, House of Delegates

### FIRST MEETING

Oregon Convention Center  
Sunday, June 9, 2024  
1:00 – 5:00 p.m.

1. CALL TO ORDER
2. ROLL CALL OF DELEGATES
3. REPORT ON PREVIOUS SESSION
4. RATIFICATION OF PREVIOUS ACTIONS
5. REPORT OF THE COMMITTEE ON NOMINATIONS
6. REPORT OF THE COMMITTEE ON RESOLUTIONS
7. STATEMENTS OF CANDIDATES, HOUSE OF DELEGATES CHAIR
8. BOARD OF DIRECTORS REPORTS
  - a. COUNCIL ON PHARMACY PRACTICE  
Jennifer Tryon, Board Liaison
  - b. COUNCIL ON PUBLIC POLICY  
Vivian Bradley Johnson, Board Liaison
  - c. COUNCIL ON THERAPEUTICS  
Vickie Powell, Board Liaison
  - d. COUNCIL ON EDUCATION AND WORKFORCE DEVELOPMENT  
Kristi Gullickson, Board Liaison
  - e. COUNCIL ON PHARMACY MANAGEMENT  
Kim Benner, Board Liaison
  - f. SECTION OF COMMUNITY PHARMACY PRACTITIONERS  
Pamela Phelps, Board Liaison
9. REPORT OF THE TREASURER
10. RECOMMENDATIONS OF DELEGATES
11. ANNOUNCEMENTS

12. ADJOURNMENT OF FIRST MEETING

## SECOND MEETING

Oregon Convention Center  
Tuesday, June 11, 2024  
4:00 – 6:00 p.m.

1. CALL TO ORDER
2. QUORUM CALL
3. ELECTION OF THE CHAIR OF THE HOUSE OF DELEGATES
4. REPORT OF THE COMMITTEE ON RESOLUTIONS
5. UNFINISHED AND NEW BUSINESS
6. REPORT OF THE PRESIDENT AND THE CEO  
Nishaminy Kasbekar and Paul Abramowitz
7. RECOMMENDATIONS OF DELEGATES
8. INSTALLATION OF OFFICERS AND DIRECTORS
9. ANNOUNCEMENTS
10. ADJOURNMENT OF SECOND MEETING

# House of Delegates

## AGENDA

### First Delegate Caucus

June 9, 2024

9:30 – 11:30 a.m.

Oregon Convention Center, Room C123

---

The First Delegate Caucus has two purposes:

- 1) To review the agenda for the first meeting of the House of Delegates and answer questions delegates have about the agenda.
  - 2) To facilitate the work of delegates who wish to amend policy recommendations.
- 

#### 1. Review of First Meeting Agenda

1. Call to Order
2. Roll Call of Delegates
3. Report on Previous Session
4. Ratification of Previous Actions
5. Report of Committee on Nominations
6. Report of Committee on Resolutions
7. Statements of Candidates, House of Delegate Chair
8. Board of Directors Reports:
  - A. Council on Pharmacy Practice
  - B. Council on Public Policy
  - C. Council on Therapeutics
  - D. Council on Education and Workforce Development
  - E. Council on Pharmacy Management
  - F. Section of Community Pharmacy Practitioners
9. Report of the Treasurer
10. Recommendations of Delegates
11. Announcements
12. Adjournment of First Meeting

#### 2. Amendments to Policy Recommendations

# House of Delegates

## AGENDA

### Second Delegate Caucus

June 11, 2024

12:15 – 2:00 p.m.

Oregon Convention Center, Room C123

---

The Second Delegate Caucus has four purposes:

- 1) To review the agenda for the second meeting of the House of Delegates and answer any questions delegates have about the agenda.
  - 2) To review the Report of the Committee on Resolutions and provide an opportunity for delegate discussion of the resolution and the Committee's recommendation.
  - 3) To present the Board's actions on policy recommendations amended by the House ("unfinished business").
  - 4) To present new business items coming before the House.
- 

#### **1. Review of Agenda**

1. Call to Order
2. Quorum Call
3. Election of the Chair of the House of Delegates
4. Report of the Committee on Resolutions
5. Unfinished and New Business
6. Report of the President and the CEO
7. Recommendations of Delegates
8. Installation of Officers and Directors
9. Announcements
10. Adjournment of Second Meeting

#### **2. Report of the Committee on Resolutions**

#### **3. Unfinished Business**

#### **4. New Business**



ASHP Regional Delegate Conferences  
April 27–30, 2024

Antitrust Statement

ASHP has a policy of strict compliance with federal and state antitrust laws. ASHP policymakers, including delegates to the House of Delegates, need to be aware of the possible antitrust exposure that may arise when representatives of competing entities with market power meet to discuss the types of issues on House of Delegates agendas. Although your service in the ASHP House of Delegates has as its express purpose carrying on discussions for the purpose of optimizing therapeutic outcomes and patient care, and is a voluntary venture, not undertaken on behalf of your respective employers or businesses, your activities may be interpreted as actions by competitors. It is important that delegates understand that they cannot come to understandings or agreements on activities or positions that might:

- 1) raise, lower or affect prices, reimbursement levels, discounts, fees, wages, and/or other terms and conditions for doing business;
- 2) allocate or divide markets or territories;
- 3) indicate a refusal to deal with particular customers, companies, or third-party payors; or
- 4) affect supply and demand of products and/or services.

It is acceptable to discuss pricing models, methods, systems, and other forms of voluntary consensus standards or guidelines based on objective evidence that do not lead to an agreement on restraining prices, wages, or related matters. Information may be presented with regard to historical pricing activities so long as such information is general in nature and does not include specific data on current prices or wages in a particular trade area. Any discussion by delegates to the ASHP House of Delegates of current or future pricing, wages, fees, or other terms and conditions, which may lead to an agreement or consensus on prices, wages, or fees, is strictly prohibited. A violation of the antitrust laws may be inferred from discussions about pricing or wages followed by parallel decisions by group members, even in the absence of an oral or written agreement.

# House of Delegates

---

April 18, 2024

## MEMORANDUM

**TO:** Delegates and Alternate Delegates  
2024 ASHP House of Delegates

**FROM:** Paul W. Abramowitz, PharmD, ScD (Hon), FASHP  
Chief Executive Officer

**SUBJECT:** Candidates for ASHP Offices

---

The ASHP Committee on Nominations met on April 17, 2024, and prepared a slate of candidates for President and Board of Directors. The following slate will be presented to the House of Delegates on Sunday, June 9, 2024.

### President, 2025-2026

**Melanie A. Dodd, PharmD, PhC, BCPS, FASHP**  
Associate Dean for Clinical Affairs and Professor  
The University of New Mexico College of Pharmacy  
Albuquerque, NM

**Stephen F. Eckel, PharmD, MHA**  
Associate Dean  
UNC Eshelman School of Pharmacy  
Chapel Hill, NC

### Board of Directors, 2025-2028

**Marie A. Chisholm-Burns, PharmD, PhD, MPH,  
MBA, FACHE, FASHP, FAST**  
Executive Vice President & Provost  
Oregon Health & Science University  
Portland, OR

**Todd W. Nesbit, PharmD, MBA, CPEL, FASHP**  
Vice President & Chief Pharmacy Officer  
The Johns Hopkins Health System  
Baltimore, MD

**Mollie A. Scott, PharmD, BCACP, CPP, FASHP,  
FNCAP**  
Regional Associate Dean and Clinical Professor  
UNC Eshelman School of Pharmacy  
Asheville, NC

**Majid R. Tanas, PharmD, MHA, MS, FASHP**  
Vice President of Pharmacy and Chief Pharmacy Officer  
Legacy Health  
Portland, OR

### Chair, House of Delegates, 2024-2027

**Jesse H. Hogue, PharmD**  
Pharmacy Education Coordinator  
Bronson Methodist Hospital Inpatient Pharmacy  
Kalamazoo, MI

**Martin J. Torres, PharmD, FCSHP**  
Director of Pharmacy, Quality, Safety, Education,  
and Research  
UC Irvine Medical Center Pharmacy Department  
Orange, CA

---

Members are invited to “Meet the Candidates” on Monday, June 10, 12:15 – 1:45 pm, in Room C123 of the Oregon Convention Center. The new Chair of the House of Delegates will be elected and installed on Tuesday, June 11, during the second meeting of the House. Election of the ASHP President 2025-2026 and members of the Board of Directors will occur during the annual balloting in June.

# 2024 Report of the ASHP Treasurer

**Christene M. Jolowsky**

The Treasurer has the responsibility to report annually on ASHP's financial condition to the membership. ASHP's fiscal year is from June 1 through May 31, coinciding with our policy development process and timetable. This report describes ASHP's actual financial performance for fiscal year FY2023, projected financial performance for FY2024, and an FY2025 budget status update.

### **Fiscal Year 2023 Ending May 31, 2023—Actual**

ASHP's FY2023 financial statement audit for the year ending May 31, 2023, was performed by Aprio, LLP. The audit resulted in ASHP receiving the best opinion available, an unmodified opinion.

ASHP's core operations<sup>1</sup> experienced a strong post-COVID recovery. Core gross revenue was \$58.8 million (Figure 1), up by \$15.0 million compared to FY2022. The gross revenue increase was primarily attributable to the Midyear Clinical Meeting & Exhibition (MCM) being held in person versus a virtual meeting during FY2022. In addition, we held the Summer Meetings for the first time after a two-year hiatus due to COVID and had successes with membership, *American Journal of Health-System Pharmacy (AJHP)*, special publishing, professional certificates, accreditation services, and the Health and Human Services Administration grant. Core net income was a surplus of \$4.4 million. Net program development, capital budget, and investments<sup>2</sup> were a net loss of \$1.9 million, which is attributable to short-term investment losses. In total, FY2023 resulted in a favorable \$2.5 million net change in ASHP's reserves/net assets.

Finally, the building fund<sup>3</sup> had a loss of \$4.9 million, primarily due to short-term investment losses. With significant positive returns in previous years, the building fund remains on track to continue supporting ASHP's office space expenses and reach its long-term financial target. ASHP's total net assets at the end of FY2023 were \$134.6 million (Figure 2). Our year-end balance sheet remained strong, with an asset-to-liability ratio of 3.95:1. ASHP remains well-prepared for the future.

---

<sup>1</sup>Represents the revenue and expense associated with the operations of ongoing ASHP programs, products, and services, as well as infrastructure and ASHP Foundation support.

<sup>2</sup>Includes investments in ASHP's program development and capital budget, building sale reserve funds, reserves/net assets spending, and investment gains/(losses). The Board of Directors approves spending during ASHP's annual budget development process. Expenditures are typically (1) associated with new, enhanced, and expanded programs; (2) associated with time-limited programs; (3) capital asset purchases; or (4) supplemental operating expenses. These expenditures are primarily funded by investment income from reserves/net assets and the building sale reserve funds.

<sup>3</sup>Created to hold the net gain from the sale of ASHP's previous headquarters building. The long-term investment earnings are used to pay for lease and other occupancy-related expenses associated with ASHP's current headquarters office.

## Report of the ASHP Treasurer

### Fiscal Year 2024 Ending May 31, 2024—Projected

Fiscal year 2024 core operations are shaping up to have another record year, with projected core gross revenue of \$61.0 million. As of February 29, 2024, we anticipate that ASHP's FY2024 core net income will be in the range of \$1.7 million (Figure 1). Assuming the financial markets remain steady for the remainder of the fiscal year, we are projecting a deficit of \$443,000 for program development expenses, capital budget, and investments. This deficit is primarily due to ASHP's current year \$1.5 million investment in a national public awareness campaign to educate the public about the roles of pharmacists and pharmacy personnel in hospitals, health systems, and clinics. This results in a projected positive net change in reserves/net assets of \$1.3 million. Finally, we anticipate the building fund will have a surplus in the range of \$17,000.

ASHP accomplished a great deal during FY2024, including maintaining a strong and active membership and launching The Pharmacy Technician Society (TPTS), a stand-alone 501(c)6 membership organization for pharmacy technicians. Initial interest and engagement with TPTS has been strong. The aforementioned national public awareness campaign launched to a strong positive reaction. We continue to build back our in-person meetings and remain at the forefront of pharmacy training and education.

ASHP's engaged and growing membership is a testament to our efforts to help pharmacy practitioners address today's most pressing challenges and prepare for dynamic changes ahead. As the largest and most influential professional pharmacy organization in the United States, ASHP remains dedicated to addressing the individualized and evolving needs of our members in every practice setting and at every step of their careers.

### Fiscal Year 2025 Ending May 31, 2025—Budget

ASHP's Board of Directors has thoughtfully considered our FY2025 budget. There are many positive signs for the future.

We look forward to continuing to grow our MCM and Pharmacy Futures meeting (formerly the Summer Meetings), expanding our membership, and achieving many successes as we invest in and nurture our publications, professional development, accreditation, and other programs. As our workforce evolves and changes, the Board of Directors continues to position ASHP for the future to ensure we can support our members and the profession with timely and valuable resources, products, and services.

Considering these and other factors, ASHP's FY2025 budgeted net change in reserves/net assets is a deficit of \$559,000, with \$60.4 million in core gross revenue. The deficit is primarily attributable to ASHP's continued investment in the national public awareness campaign. The building fund, which is designed to pay for ASHP's headquarters office space, is budgeted to have a \$323,000 surplus.

### Conclusion

As ASHP works to support our members, the profession, and the patients we serve through this transformative era, we have experienced sustained financial stability and membership growth. ASHP proudly represents the diversity and vibrancy of the pharmacy profession. Effective financial stewardship, innovative thinking, and a collaborative spirit ensure that we have a strong pipeline of products, programs, and services to enhance practice, foster career

## Report of the ASHP Treasurer

development, and most importantly, positively impact safe and effective medication use and improved patient outcomes. The Board of Directors, Chief Executive Officer, and staff are wholly dedicated to ASHP’s mission, vision, and strategic plan and supporting our members. We look forward to another successful year, and I am proud to serve this organization as your Treasurer!

**Figure 1. ASHP Condensed Statement of Activities (in thousands)**

	Actual Fiscal Year 2022 Ended May 31, 2022	Actual Fiscal Year 2023 Ended May 31, 2023	Projection* Fiscal Year 2024 Ended May 31, 2024	Budget Fiscal Year 2025 Ended May 31, 2025
<b>CORE OPERATIONS</b>				
Gross Revenue	43,848	58,775	61,015	60,370
Total Expense	(47,996)	(54,384)	(59,295)	(60,367)
<b>CORE NET INCOME/(LOSS)</b>	<b>(4,148)</b>	<b>4,391</b>	<b>1,720</b>	<b>3</b>
<b>NET PROGRAM DEVELOPMENT EXPENSES, CAPITAL BUDGET, AND INVESTMENTS GAIN/(LOSS)</b>				
	(4,227)	(1,929)	(443)	(562)
<b>NET CHANGE IN RESERVES/NET ASSETS</b>	<b>(8,375)</b>	<b>2,462</b>	<b>1,277</b>	<b>(559)</b>
<b>BUILDING FUND</b>	<b>(8,671)</b>	<b>(4,867)</b>	<b>17</b>	<b>323</b>

\*Projection as of February 29, 2024

**Figure 2. ASHP Statement of Financial Position (in thousands)**

	Actual as of May 31, 2022	Actual as of May 31, 2023
<b>ASSETS</b>		
Current assets	12,496	22,204
Fixed assets	4,644	3,851
Investments	150,601	141,424
Other assets	478	12,850
<b>Total Assets</b>	<b>168,219</b>	<b>180,329</b>
<b>LIABILITIES</b>		
Current liabilities	22,615	27,783
Long-term liabilities	8,556	17,903
<b>Total Liabilities</b>	<b>31,171</b>	<b>45,686</b>
<b>RESERVES/NET ASSETS</b>		
Total Net Assets	137,048	134,643
<b>Total Liabilities and Net Assets</b>	<b>168,219</b>	<b>180,329</b>